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ABSTRACT
SIGNALING MECHANISMS FOR MUSCARINIC RECEPTOR-MEDIATED 
CORONARY VASOCONSTRICTION IN ISOLATED RAT HEARTS
by 
Yi Zhang
The signaling mechanisms for muscarinic receptor-mediated vasoconstriction in coronary 
resistance arteries were studied in KCl-arrested isolated rat hearts perfused at a constant 
flow rate. The cholinergic agonists acetylcholine and bethanechol were given by bolus 
injection or constant infusion. The coronary vascular resistance was monitored by 
measuring the changes in perfusion pressure.
The selective muscarinic agonist bethanechol caused a similar vasoconstrictor response as 
ACh, but with less potency and efficacy. Bolus injection o f bethanechol evoked a phasic 
vasoconstriction in a dose-dependent manner, while infusion o f bethanechol evoked a 
tonic vasoconstriction without producing tachyphylaxis. Coronary vascular responses to 
bethanechol were further examined in the absence and presence of a specific inhibitor or 
blocker for the potential signaling components.
The bethanechol-induced phasic vasoconstriction was eliminated by perfusion with a 
Ca2+-ffee medium. The maximal vasoconstriction to bethanechol was suppressed by 31% 
in the presence of the Ca2+-dependent Cl'-channel blocker A-9-C. The L-type voltage- 
operated Ca2+ channel blocker nifedipine decreased the maximal constrictor response to 
bethanechol by 59%, while the putative receptor-operated Ca2+ channel blocker SK&F 
96365 converted this vasoconstriction into vasodilation which was not affected by the 
nitric oxide synthase inhibitor L-NAME. Coronary vascular responses to bethanechol 
were almost abolished by a combination o f  nifedipine and SK&F 96365. The protein 
kinase C inhibitor chelerythrine reduced bethanechol-evoked peak vasoconstriction by 
79%. The bethanechol-induced tonic vasoconstriction was rapidly converted into 
vasodilation by the concomitant infusion o f SK&F 96365 or nifedipine, but the 
simultaneous infusion o f chelerythrine gradually attenuated this response.
These data suggest that the novel receptor-operated Ca2+ channel, voltage-operated Ca2" 
channel, and protein kinase C are the most crucial signaling components for muscarinic 
receptor-mediated coronary vasoconstriction in the isolated rat heart. Extracellular Ca2+ 
influx via receptor-operated Ca2+ channels and voltage-operated Ca2+ channels is 
essential to both phasic and tonic vasoconstrictor responses to bethanechol. Protein 
kinase C plays a pivotal role in the regulation o f bethanechol-evoked vasoconstriction by 
sensitizing the contractile apparatus and modulating the activity o f Ca2+ channels.
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CHAPTER 1 
INTRODUCTION
Background
Cholinergic Mechanism in Coronary Vasculature
It is well established that parasympathetic innervation plays an important role in 
the regulation o f the coronary circulation. The neurotransmitter acetylcholine (ACh) 
released from vesicles in parasympathetic nerve terminal, binds to muscarinic receptors 
on coronary vessels and evokes vascular responses. Histochemical studies have 
demonstrated that coronary artery of man and various animal species is innervated by 
nerve fibers which are identified as cholinergic by their intense staining for 
acetylcholinesterase (Kalsner, 1989; Feigl, 1998). These fibers are presumed to originate 
from postganglionic neurons o f the cardiac parasympathetic ganglia which are innervated 
by the vagus nerve.
Physiological and pharmacological evidence also supports the presence and 
function of cholinergic innervation of coronary vessels. Most o f the functional evidence 
for cholinergic regulation o f coronary circulation has been obtained from experiments 
with dogs (Feigl, 1984). Electrical stimulation of the vagus nerve produces vasodilation 
with an increase o f coronary blood flow in this species. In contrast, coronary 
vasoconstrictor responses to cholinergic stimulation or ACh injection are more prominent 
in human and several other animal species, such as rat, pig, sheep, cow and simian (Van 
Charldrop et al., 1987; Kalsner, 1989; Angus et al., 1991). Cholinergic stimulation-
1
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2mediated coronary vasoconstriction in calves is enhanced by the cholinesterase inhibitor 
physostigmine and blocked by the nonselective muscarinic receptor antagonist atropine 
(Kalsner, 1979). Cholinergic activation is also observed to contract the coronary 
resistance vessels through muscarinic receptors in the rat, pig and human (Bognar et al., 
1990; Kalsner, 1989; Angus, etal., 1991).
As reviewed by Kalsner (1989), ACh injection causes a coronary vasoconstriction 
in patients with variant angina or coronary stenosis but has no effect in patients pretreated 
with atropine. These observations provide evidence for the involvement o f cholinergic 
mechanisms and muscarinic receptors in the pathology of coronary vasoconstriction.
Muscarinic Receptor-Mediated Coronary Vascular Responses
The coronary vasculature contains muscarinic receptors in both smooth muscle 
and endothelium layers (Fig. 1). The characteristics of response to muscarinic agonist are 
species-dependent (Kalsner, 1989; Feigl, 1998), and can be affected by pathological 
conditions (Ludmer et al., 1986; Treasure et al., 1992; Egashira et al., 1995). The 
muscarinic receptor subtype present in the coronary vasculature has been evaluated for 
several animal species by functional experiments with selective muscarinic antagonists. 
The results from these studies are consistent with the conclusion that the M3 muscarinic 
receptor subtype mediates both coronary vasodilation and vasoconstriction (Van 
Charldorp and Van Zwieten, 1989; Duckies, 1990; Brunner et al., 1991; Ren et al., 1993; 
Boulanger et al., 1994; Hoover and Neely, 1997).
In terms of the various vascular responses to cholinergic agonists, there might 
exist substantial species differences in the density and distribution o f muscarinic
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3receptors in coronary vessels. As shown in Fig. 1, much o f the difference among species 
is probably explained by the relative strength o f the direct vasoconstrictor effect o f ACh 
on vascular smooth muscle and the secondary endothelium-dependent vasodilator effect 
(Kalsner, 1989). Vasoconstriction is mediated directly by the activation o f muscarinic 
receptors located on vascular smooth muscle cells and indirectly by endothelium-derived 
contacting factors, while vasodilation is a solely indirect effect that results from the 
stimulation o f muscarinic receptors on endothelium and is mediated by endothelium- 
derived relaxing substances (Furchgott and Vanhoutte, 1989). Accordingly, the nature o f 
the response to muscarinic agonists depends on the relative abundance o f  receptors at 
these sites. For instance, ACh causes a constrictor effect on human small coronary 
arteries even in the presence of intact endothelium, and it is proposed that the population 
of muscarinic receptors on the medial smooth muscle predominates over that on the 
endothelium (Angus et al., 1991).
The effect o f ACh on normal human epicardial arteries has varied among studies. 
Some investigators observe vasodilation (Ludmer et al., 1986; Bossaller et al., 1987; 
Egashira et al., 1995) whereas others find only vasoconstriction (Kalsner, 1989; Toda and 
Okamura, 1989). However, vasoconstriction is either the sole or dominant response of 
epicardial arteries in patients with atherosclerosis or hypertension (Ludmer et al., 1986; 
Hodgson and Marshall, 1989; Treasure et al., 1992; Egashira et al., 1995), indicating that 
endothelial dysfunction might occur in these pathological conditions.
Role of Endothelium in Contraction o f  Vascular Smooth Muscle
As presented in Fig. 1 and Fig. 3, the endothelial lining can regulate coronary
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
vascular tone by releasing a number o f dilators and constrictors (Furchgott, 1983; 
Schachinger and Zeiher, 1996).
The relaxing substances generated by endothelium include EDRF (identified as 
nitric oxide or related nitrogen-containing compounds) and a still hypothetical EDHF 
(Furchgott and Vanhoutte, 1989). Nitric oxide relaxes smooth muscle by activating 
soluble guanylyl cyclase (Vanhoutte, 1992). EDHF might be a derivative of arachidonic 
acid and/or some other factor which can open K+ channels and produce hyperpolarization 
(Furchgott and Vanhoutte, 1989). Another well-known endothelium-derived vasodilator 
is prostacyclin (PGI2), the major arachidonic acid metabolite found in most endothelial 
cells (Ost et al., 1998).
The identity o f EDCF has not been determined so far, but it appears to be some 
unstable product o f COX that activates TxA2/prostaglandin H2 receptors on vascular 
smooth muscle (Auch-Schwelk et al., 1990). TxA2, cyclic endoperoxides and 
leukotrienes are all proposed as endothelium-dependent vasoconstrictors (Luscher et al., 
1992). Other candidates for EDCF include superoxide anions and possibly endothelins 
(Furchgott and Vanhoutte, 1989).
Endothelium-Derived Dilating Substances in Muscarinic Receptor-Mediated Vascular 
Responses
Accumulated evidence demonstrates that ACh dilates various blood vessels by 
stimulation of muscarinic receptors on the endothelium, and this vasodilation is mediated 
by EDRF and/or EDHF (Peach et al., 1985; Chen et al., 1988; Furchgott & Vanhoutte, 
1989; Schini and Vanhoutte, 1992; Yang et al., 1992; Hammarstrom et al., 1995). In rat
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
aorta, ACh causes an endothelium-dependent relaxation, which is mediated by the 
activation of a constitutive, calmodulin-dependent nitric oxide synthase and the 
subsequent production o f nitric oxide (Schini and Vanhoutte, 1992). Pretreatment o f 
isolated rat hearts with the NO synthase inhibitor N^monomethyl-L-arginine or guanylyl 
cyclase inhibitor methylene blue potentiated the ACh-evoked vasoconstriction, 
suggesting that the vasoconstrictor response to ACh is normally attenuated by basal and 
stimulated EDRF release (Yang et al., 1993).
Activation of M3 muscarinic receptors by ACh also evokes vasodilation in guinea 
pig coronary arteries by releasing EDHF, which was identified by recording the 
membrane potential with intracellular microelectrodes (Hammarstrom et al., 1995). On 
the other hand, ACh elicits only contraction in endothelium-denuded guinea pig coronary 
arteries by depolarizing the smooth muscle cell membrane (Nashiye et al., 1990).
Ca2+-channel openers trigger the release o f EDRF in a variety o f perfused arteries, 
this response is prevented by the L-type VOCC blocker dihydropyridines, indicating that 
the vascular endothelial membrane must contain VOCCs. However, the increase in 
cytoplasmic Ca2+ that stimulates EDRF release in response to ACh is not due to 
activation of these channels (Vanhoutte, 1988). In bovine isolated coronary arteries, 
EDHF-mediated vasodilation was also shown to be independent o f VOCC activity 
(Drummond and Cocks, 1996). These data suggest that although extracellular Ca2" influx 
is necessary for the release o f EDRF and EDHF from coronary endothelial cells, Ca2+ 
influx through VOCCs does not play a role in this process.
Endothelium-Derived Contracting Substances in Muscarinic Receptor-Mediated Vascular
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Responses
TxA2 is produced in response to ACh in rabbit pulmonary arteries (Altiere et al.,
1986). At least a portion o f  the vasoconstrictor response to ACh in spontaneously beating 
rat hearts could occur by an endothelium-dependent mechanism since this effect is 
reduced in the presence o f  a TxA2 receptor antagonist (Yang et al., 1993). Studies from 
Kato et al. (1990) suggest that prostaglandin H2 plays an important role in endothelium- 
mediated contraction produced by muscarinic stimulation in rat aorta. In addition, 
activation o f TxA2/prostaglandin H2 receptors appears to be necessary for the ACh- 
induced cerebral vasoconstriction to occur (Armstead et al., 1989). Moreover, a study 
conducted by Jino et al. (1996) demonstrated that ACh evoked both endothelium- 
dependent and independent contractions o f rabbit left coronary arteries. It is concluded 
that the ACh-induced endothelium-dependent contraction is due to leukotrienes which 
have been shown to be potent vasoconstrictors, particularly in coronary arteries (Kito et 
al., 1981; Michelassi et al., 1982; Hu et al., 1991; Han et al., 1994).
Overall Effect o f ACh in Coronary Arteries
In review o f  the literature, three possible effects produced by ACh in coronary 
vessels via activating muscarinic receptors are summarized as following: ( 1) 
endothelium-dependent relaxation mediated by EDRF, presumably identical with nitric 
oxide (Palmer et al., 1987), and/or by EDHF (Taylor and Weston, 1988); (2) 
endothelium-dependent contraction mediated by eicosanoids and/or by EDCF (Furchgott 
and Vanhoutte, 1989); (3) endothelium-independent contraction mediated by direct 
stimulation o f muscarinic receptors on smooth muscle (Kalsner, 1989). The overall
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7response o f coronary vessels to ACh depends upon the final summation o f all three 
effects.
ACh causes a coronary vasodilation through the release o f nitric oxide in perfused 
rabbit and guinea pig hearts (Amezcua et al., 1988; Ellwood and Curtis, 1996), while 
ACh and other cholinergic agonists produce a coronary vasoconstriction in perfused rat 
hearts (Nuutinen et al., 1985; Yang et al., 1993; Hoover and Neely, 1997). In isolated 
coronary arterial segments, ACh exerts a vasodilator effect in dog and monkey, while it 
causes a vasoconstriction in human, sheep and pig (Kalsner, 1989). As in most cases, the 
contractile responses to vasoactive agents are diminished by basal or stimulated release of 
EDRF. When coronary vascular endothelium is removed from the isolated guinea pig 
heart, the vasodilator response to ACh is replaced with a vasoconstriction, as a result of 
the direct effect o f  ACh on vascular smooth muscle (Wiest et al., 1989). In addition, 
endothelial cells can release vasoconstrictive substances such as prostaglandins and 
leukotrienes. Thus, ACh appears to have a complex and species-dependent effect on the 
coronary circulation.
In summary, the ACh-evoked vasodilation is completely dependent upon the 
presence of intact endothelium in coronary vessels. In endothelium-removed vascular 
arterial segments, ACh produces only a vasoconstriction rather than a vasodilation. 
Therefore, the nature o f the vascular response to ACh is due to the results from both 
endothelium-dependent and independent effects.
General Mechanisms for Contraction o f Smooth Muscle
A two-phase model for smooth muscle contraction has been postulated and
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described by Rasmussen et al. (1987). Similarly, agonist-evoked vasoconstriction usually 
involves rapid phasic and tonic components which are thought to occur through different 
pathways o f excitation-contraction coupling. It is proposed that fP3 generation and Ca2+ 
mobilization are responsible for rapid tension development, whereas PKC regulates the 
maintenance of contraction when intracellular Ca2+ concentration is low. Development o f 
force is associated with an increase in the cytosolic Ca2^  concentration due to Ca2+ release 
from intracellular stores via EP3-sensitive and/or ryanodine-sensitive Ca2+ channels in 
sarcoplasmic reticulum, and extracellular Ca2+ entry across cell membrane. This increase 
in cytosolic Ca2+ concentration causes Ca2+-calmodulin-dependent activation of MLCK. 
Sustained tension development can occur without prolonged elevation o f cytosolic Ca2+ 
concentration. This phenomenon led investigators to postulate the “latch bridge”, a cross 
bridge without recycling or recycling very slowly to maintain smooth muscle contraction 
(Murphy et al., 1983; Hai and Murphy, 1989). Rasmussen et al. (1987) further proposed 
that PKC-mediated phosphorylation and rearrangement o f intermediate filaments may 
function to maintain such sustained contraction in smooth muscle. Moreover, the time 
course o f intermediate filament protein phosphorylation has been correlated positively 
with that o f sustained force development.
Signaling Mechanisms for Muscarinic Receptors
Muscarinic receptors, composed of a single protein with seven transmembrane 
domains, couple with G-proteins and trigger the intracellular signal transduction 
pathways which regulate the activity of a number of effector enzymes and ion channels.
As reviewed by Felder (1995), five subtypes o f muscarinic receptor (ml-m5) have been
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9identified by molecular genomic cloning studies and much has been learned about their 
distribution, pharmacology and structure. The ectopic expression o f genes encoding a 
single muscarinic receptor subtype in mammalian cell lines has provided an important 
model system for investigating receptor subtype-specific pharmacology and signal 
transduction. It has been widely accepted that m l, m3 and m5 subtypes can trigger 
multiple signaling mechanisms simultaneously including PLA2 and PLC, as well as Ca2+ 
channels; m2 and m4 subtypes can augment PLA2 in addition to their established role as 
inhibitory receptors by attenuation o f adenylyl cyclase activity.
Many functional studies have consistently implicated the M3 muscarinic receptor 
subtype in the coronary vasoconstrictor effect of ACh in various animal species, 
including pig and rat (Van Charldorp and Van Zwieten, 1989; Hoover and Neely, 1997). 
Evidence from molecular genomic cloning studies has revealed that m3 muscarinic 
receptors can activate PLC, PLA2, a novel class of voltage-independent Ca2+ channels and 
also stimulate VOCCs in excitable cells, such as neurons and muscles. Receptor- 
activated and Ca2^  influx-dependent phospholipases have been suggested to be integral 
membrane proteins located adjacent to both receptors and channels (Caulfield, 1993; 
Felder, 1995). The phospholipases may also translocate to the membrane following 
activation to gain access to the continuous Ca2+ flow (Cobum et al., 1997). Ca2+ influx 
seems to play a very important role in the regulation o f multiple signaling pathways and 
vasoconstriction mediated by muscarinic receptors (Su and Narayanan, 1993). Although 
the molecular mechanisms coupling to the muscarinic receptor-mediated contraction of 
coronary vascular smooth muscle have not yet been well defined, the hypothetical signal 
transduction mechanisms for M3 muscarinic receptor-mediated coronary vasoconstriction
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are shown in Fig. 2.
Role of Ca2+ and Ca2* Channels in Contraction of Vascular Smooth Muscle
The central role o f Ca2+ as a second messenger and a regulator o f  effector 
enzymes in signaling for vascular smooth muscle contraction has been well established 
(Berridge, 1997). As illustrated in Fig. 2, agonist-evoked vasoconstiction involves an 
increase in intracellular Ca2+ concentration and subsequent phosphorylation o f myosin 
light chain by Ca27calmodulin-activated MLCK (Rembold and Murphy, 1988). 
Phosphorylation o f the 20-kDa regulatory light chains o f myosin activates actinomyosin 
ATPase and initiates cross-bridge cycling o f myosin along actin filaments to produce 
contraction. The contraction o f vascular smooth muscle differs from that o f most visceral 
smooth muscle and myocardial cells in that Ca2+ influx usually occurs with relatively 
small membrane depolarizations, the absence of action potentials, and can be sustained 
over many seconds and minutes (Malarkey et al., 1996).
As indicated in Fig. 2, the vascular smooth muscle cell membrane is spanned by a 
number of types o f Ca2_r channels which act in a co-ordinated fashion to regulate Ca2+ 
influx upon receptor stimulation, thereby contributing to the control o f  intracellular Ca2+ 
concentration and hence vascular constriction. The major Ca2+ entry channels have been 
classified on the basis of their regulatory mechanism: VOCCs, ROCCs and SOCCs 
(Fasolato et al., 1994). These channels have very different kinetic properties in that the 
VOCCs and ROCCs usually provide brief high intensity bursts whereas the SOCCs 
provide a much smaller but sustained influx o f Ca2+ (Berridge, 1997). While the 
operation of the VOCCs and ROCCs is reasonably well understood, the signaling of
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SOCCs is still very much o f a mystery and may also be cell type-dependent (Clementti 
and Meldolesi, 1996).
In excitable cells, such as neurons and muscle cells, Ca2+ influx occurs 
predominantly through VOCCs which open in response to membrane depolarization. In 
nonexcitable cells, such as fibroblasts and epithelial cells, Ca2+ influx is mainly through a 
family of poorly characterized VICCs. VICCs constitute a large family o f proteins, with 
different family members being expressed in excitable and nonexcitable cells, each with 
their own regulatory mechanism and biological function (Felder et al., 1994). VICCs 
open in response to receptor activation and have been classified into three general groups: 
(1) ROCCs, which are membrane potential- and second messenger-insensitive, but tightly 
couple to receptor and have extremely low conductance; (2) SOCCs, which are regulated 
by the concentration o f Ca2+ within the intracellular store, open after fP3-mediated Ca2r 
depletion from the store and provide a source o f Ca2+ for refilling the store; (3) SMOCCs, 
which are regulated by Ca2+ itself, IPj, IP4, or other second messengers released following 
receptor activation, but independent of the filling state of intracellular Ca2+ stores. The 
role of SOCCs in refilling EP3-sensitive pools is now firmly established. The 
identification and characterization of ROCCs and SMOCCs have occurred only recently, 
therefore, their physiologic role is still somewhat speculative.
Role of Ca2+ and Ca2+ Channels in Muscarinic Receptor-Mediated Contraction
M3 muscarinic receptors stimulate increases in cytosolic Ca2+ concentration via 
Ca2+ channels in both sarcoplasmic reticulum and plasma membrane. The changes in 
intracellular Ca2+ concentration are characterized by a rapid and transient spike, followed
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by a plateau phase that is maintained as long as the muscarinic agonist is present in the 
extracellular media (Felder, 1995). A similar phenomenon is described in ACh- 
stimulated single smooth muscle cells from the porcine coronary arteries (Itoh et al.,
1988). In addition, the study conducted by Katsuyama et al. (1991) in the porcine 
coronary vascular smooth muscle cells has provided evidence that ACh releases Ca2+ 
from the ryanodine-sensitive sarcoplasmic reticulum and produces a contraction by a 
Ca2+-induced Ca2+ release mechanism.
It is generally agreed that the muscarinic receptor-mediated Ca2+ transient spike 
represents the release o f Ca2+ from EP3-sensitive intracellular stores which may be 
responsible for initiation o f vasoconstriction (Berridge, 1993). The sustained plateau 
phase is attributed to the extracellular Ca2+ influx through a family o f Ca2+ channels that 
are directly linked to receptors (ROCCs), open in response to membrane depolarization 
(VOCCs) and are activated by the depletion of Ca2" intracellular stores (SOCCs) (Felder,
1995). The muscarinic receptor-mediated activation o f VICCs has not been well 
characterized so far. Indirect evidence by using Ca2+ sensitive fluorescent intracellular 
probes supports a significant role for M3 muscarinic receptors in interaction with all 
known VICCs, including ROCCs, SOCCs and SMOCCs (Felder et al., 1994).
Ca2+ influx may have the predominant contribution to maintenance of the 
muscarinic receptor-mediated vasoconstriction. Ca2+ entry mainly through VOCCs and 
ROCCs has been considered to finely regulate the muscarinic receptor-induced activation 
of multiple effector pathways (Caulfield, 1993). In spite o f the extensive studies for 
exploring the roles o f Ca2+ release from intracellular stores and extracellular Ca2+ influx 
in the agonist-evoked vasoconstriction, the relative contribution of each of these
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mechanisms is still under debate (Lagaud et al., 1999). An interesting report from Low et 
al. (1996), reveals that the role o f Ca2+ release from sarcoplasmic reticulum diminishes as 
the arteries become smaller, while the role o f Ca2+ influx across the plasma membrane 
becomes more dominating.
Role of Ca2+ Influx via. VOCCs in Muscarinic Receptor-Mediated Vasoconstriction
The L-type VOCC is the most prominent Ca2+ channel in vascular smooth muscle. 
The ability o f dihydropyridines to produce vasodilation in many arteries clearly shows 
the important role o f this channel in maintaining basal vascular tone (Malarkey et al.,
1996). Furthermore, muscarinic agonist-induced Ca2+ influx through VOCCs has been 
proven to contribute to the contractile event in arterial smooth muscle (Nelson et al.,
1990). Although the L-type VOCC is regulated by membrane potential, there is 
increasing evidence that agonists such as ACh can modulate this channel activity by a 
mechanism unrelated to changes in membrane potential (Kamishima et al., 1992). Since 
ACh is linked to the PLC pathway, some intermediary o f the biochemical transduction 
mechanism is assumed to regulate VOCCs. For example, PKC has been reported to 
phosphorylate the ctj and P subunits o f the L-type VOCC from skeletal muscle (Shearman 
et al., 1989).
Coronary vasoconstrictor responses to muscarinic agonists in spontaneously 
beating rat hearts are abolished by removal o f Ca2+ from the perfusion buffer and 
decreased by the infusion of the VOCC blocker verapamil (Nuutinen et al., 1985). 
Voltage-activated Ca2+ current has been demonstrated to contribute to muscarinic agonist- 
induced vasoconstriction in rat coronary vessels (Su and Narayanan, 1993) and to be
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enhanced by muscarinic agonists in vascular smooth muscle cells as well (Clapp et al.,
1987). These studies suggest the crucial role o f extracellular Ca2+ influx and Ca2+ entry 
via VOCCs in the muscarinic receptor-mediated vasoconstriction.
Opening o f VOCCs, which mediates the VOCC blocker-sensitive component of 
smooth muscle contraction, probably results from Ca2+-activated Cl* current-induced 
depolarization (Hogg et al., 1994; Wayman et al., 1996). The muscarinic agonist 
carbachol is found to open such channels in mouse anococcygeus smooth muscle 
(Wayman, et al., 1997). Any increase in intracellular Ca2+ concentration can activate 
Ca2+-dependent Cl* channels in plasma membrane (Wayman et al., 1996). Under 
physiological conditions, activation o f Ca2+-dependent Cl* current will lead to membrane 
depolarization with a resultant opening o f VOCCs (Fig. 2). Ca2+ influx through these 
channels may account, in part, for muscarinic agonist-induced coronary vasoconstriction.
Role o f Ca2+ Tnflux via ROCCs in Muscarinic Receptor-Mediated Smooth Muscle 
Contraction
The first direct measurement o f ROCCs was performed in freshly dispersed
smooth muscle cells from rabbit ear arteries (Benham and Tsien, 1987). Ca2+ influx
through ROCCs has also been detected in cultured vascular smooth muscle cells (Xuan et
•»
al., 1992). It has been proposed that Ca2+ entry via ROCCs may provide the predominant 
Ca2+ source for the activation o f  the PLC and PLA2 pathways in many cell types (Felder 
et al., 1994).
As a consequence o f muscarinic receptor stimulation, a novel ROCC has been 
observed to conduct Ca2+ entry in cultured human airway smooth muscle cells (Murray et
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al., 1993). Similarly, M3 muscarinic receptor coupling to voltage- and intracellular 
messenger-insensitive Ca2+ channels was identified in transfected A9 fibroblasts (Singer- 
Lahatetal., 1997). The regulation o f ROCCs by muscarinic receptors probably occurs 
through a membrane-bound constituent, such as a G-protein, or through a direct receptor- 
channel interaction (Felder, 1995). The currents through ROCCs are insensitive to 
VOCC blockers and are increased by membrane hyperpolariztion, which clearly 
distinguish them from L-type VOCCs (Benham and Tsien, 1987). In addition, the 
nifedipine-resistant contraction to the muscarinic agonist carbachol in mouse 
anococcygeus smooth muscle has been attributed to ROCCs and SOCCs (Gibson et al.,
1994). Taken together, these studies suggest that ROCCs may play a role in the 
muscarinic receptor-evoked contraction o f rat coronary resistance arteries.
Role of Ca2+ Influx via SOCCs in Muscarinic Receptor-Mediated Smooth Muscle 
Contraction
As first described by Putney (1990), SOCCs are regulated by the filling state of 
intracellular Ca2+ stores through a capacitative Ca2+ entry mechanism. By analogy to an 
electrical capacitor, Ca2+ stores prevent Ca2+ entry when they are charged up but 
immediately begin to promote Ca2+ entry as soon as stored Ca2+ is discharged (Berridge,
1995). The controversial second messenger candidate for initiating capacitative Ca2+ 
entry via SOCCs is Ca2+ influx factor (CIF) (Clapham, 1995). However, the mechanisms 
for store-operated Ca2+ entry have remained elusive due to the lack o f selective inhibitors.
Stimulation o f M3 muscarinic receptors results in a rapid rise in intracellular Ca2+ 
concentration, which effectively depletes endoplasmic reticulum stores and activates Ca2+
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entry across the plasma membrane (Lechleiter et al., 1991a). Thus, activation o f M3 
muscarinic receptors probably causes IP3 -linked Ca2+ release only transiently and 
cytoplasmic Ca2+ increase may be partially prolonged by the capacitative entry 
mechanism via SOCCs. Studies conducted by Wayman et al. (1997) and Gibson et al. 
(1998) suggest that the capacitative Ca2+ entry in response to the muscarinic agonist 
appears to be important not only as a route for re-filling o f the sarcoplasmic reticulum but 
also for sustained contraction of smooth muscle from mouse anococcygeus. Therefore, 
this mechanism represents an important target for the development o f  novel and selective 
drugs. Furthermore, the Ca2+-ATPase inhibitor thapsigargin, which irreversibly blocks 
Ca2+ uptake into the intracellular store and eventually depletes the store, has been 
reported to produce an extracellular Ca2+ influx-dependent as well as a slow and sustained 
contractile response in rat aorta. The thapsigargin-induced contraction is a voltage- 
insensitive event since VOCC blockers cannot influence this effect (Noguera et al.,
1998).
The role o f capacitative Ca2+ entry through SOCCs in vascular smooth muscle has 
not been clarified so far, and the main Ca2+ entry mechanisms responsible for the ACh- 
evoked sustained cellular activation have been attributed to VOCCs and ROCCs as 
shown in Fig. 2 (Kajisuri et al., 1992). The relative contribution o f capacitative Ca2+ 
entry to excitation-contraction coupling is also proposed to depend upon the type of 
smooth muscle (Gibson et al., 1998). However, the capacitative Ca2+ entry might be 
important for the regulation o f smooth muscle tone and provide a major target for 
pharmacological intervention.
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Role ofPKC. in Vascular Smooth Muscle Contraction
As demonstrated in Fig. 2, phosphorylation o f MLC is a major determinant of 
excitation-contraction coupling in smooth muscle, while it may not explain all aspects of 
smooth muscle contractile function. It is now recognized that the phosphorylation of 
MLC20 does not totally correlate with the kinetics o f  smooth muscle contraction. 
Therefore, additional regulatory mechanisms might be involved in the contractile process 
(Horowitz et al., 1996). PKC activation has been hypothesized to be one o f the most 
important regulatory components in agonist-stimulated contraction (Rasmussen et al., 
1987). Both Ca2+-dependent (a, P) and Ca2+-independent (£, 6 ) iso forms ofPKC have 
been identified in vascular smooth muscle (Lee and Severson, 1994). Manipulation of 
PKC activity by inhibitors or down-regulation has been demonstrated to severely impair 
the contractile ability o f vascular smooth muscle (Merkel et al., 1991).
Phorbol esters as an exogenous activator ofPK C are reported to induce a 
sustained vasoconstriction (Jiang and Morgan, 1987; Park et al., 1996). Phorbol ester- 
and contractile stimulus-induced increases in membrane conventional PKC activity, 
reflective ofPKC translocation and activation in situ, have been shown in cultured 
vascular smooth muscle cells (Dixon et al., 1994; Grange et al., 1998) and intact 
preparations o f arterial smooth muscle (Singer et al., 1992). The translocation ofPKC 
from the cytosol to the membrane is proposed to be vital for phosphorylating a variety of 
smooth muscle contraction-relevant proteins (Rasmussen et al., 1987). By 
immunoblotting with isoform-specific monoclonal antibodies, PKCa and P contents in 
particulate fractions from arterial smooth muscle are shown to correlate temporally with 
increases in conventional PKC activity and tonic force maintenance following
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physiological stimuli (Singer et al., 1992).
In addition, PKC has been documented to increase Ca2+ sensitivity o f MLC 
phosphorylation and force development by inhibition o f MLC phosphatase (Itoh, et al., 
1993; Masuo et al., 1994). PKC is also demonstrated to enhance the Ca2" sensitivity of 
smooth muscle myofilaments during agonist stimulation (Rokolya et al., 1993) by 
phosphorylating the thin-filament-associated regulatory proteins such as calponin and 
caldesmon (Malarkey et al., 1996). As shown in Fig. 2, the inhibitory effects on actin 
and Mg-ATPase can be removed by the phosphorylation o f calponin and caldesmon, then 
all phosphorylated cross bridges are allowed to interact with actin for generating greater 
contraction (Winder and Walsh, 1990; Sobue and Sellers, 1991; Willis et al., 1994).
PKC is further reported to act synergistically with Ca2+ to elicit contraction in 
skinned porcine coronary arteries (Chatteqee and Tejada, 1986). The method for 
monitoring PKC localization in living vascular smooth muscle cells directly provides the 
evidence that PKC moves in a Ca2+-dependent fashion from the cytosol to the surface 
membrane simultaneously with contraction (Khalil and Morgan, 1991). On the other 
hand, PKC has been demonstrated to enhance the activity o f VOCCs in cultured 
vascular smooth muscle cells (Fish et al., 1988) and in rat aorta (Suenaga et al., 1996), 
however, the exact mechanism is still not fully understood. PKC might be particularly 
important for fine modulation of Ca2+ channel activity and membrane ion conductance by 
phosphorylation of membrane proteins such as the Ca2+-transport ATPase (Klaus and 
Klaus, 1994). The PKC-mediated pathway has also been suggested to be involved in the 
pathogenesis of coronary vasospasm in a swine model (Kodokami et al., 1996). At the 
coronary spastic sites, the Ca2+ influx through L-type VOCCs seems to be augmented by
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
19
the PKC-mediated mechanism.
Role ofPKC in Muscarinic Receptor-Mediated Vasoconstriction
The involvement of Gq and PLC-01 in the m3 muscarinic receptor signal 
transduction has been demonstrated by Sawaki and his colleagues (1993). M3 muscarinic 
receptor-mediated activation o f PLC results in the generation o f fP3 and DAG through 
hydrolysis of the membrane phospholipid PIP2. IP3 liberates Ca2+ stored in the 
sarcoplasmic reticulum by binding to the IP3-sensitive Ca2+ channel. DAG binds to and 
stimulates PKC which phosphorylates a number of intracellular proteins and modifies ion 
channels in the cell membrane (Felder, 1995; Cobum et al., 1997).
Accordingly, it is proposed that PKC may play an important role in generating 
coronary vasoconstrictor responses to cholinergic agonists. PKC involvement in the 
ACh-induced contraction has been implicated in porcine coronary arteries by using 
phorbol esters (Itoh et al., 1988). A positive correlation between conventional PKC 
translocation and the muscarinic receptor-mediated contraction is observed in intact 
arterial muscle strips (Haller et al., 1990). Further studies are needed to clarify the 
functional role ofPKC in the muscarinic receptor-mediated vasoconstriction in coronary 
resistance vessels.
Role of PLA:, COX and 5-LQX in Vascular Smooth Muscle Contraction
Vasoconstriction evoked by arachidonic acid has been attributed to the formation 
of vasoconstrictive prostaglandin and leukotriene products (Jancar et al., 1987; Kato et 
al., 1990), or a direct inhibition o f MLC phosphatase (Morimoto et al., 1990; Gong et al.,
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1992). The release o f arachidonic acid can occur either by activation o f PLA, or by a 
sequential action o f PLC and diglyceride lipase (Axelrod, 1990). The most direct 
mechanism for the release o f arachidonic acid from cellular membranes is hydrolysis of 
the primary substrate phosphatidylcholine by PLA2. Arachidonic acid is subsequently 
converted into two diverse families o f mediators (prostaglandins and leukotrienes) 
through activation o f COX and 5-LOX (Fig. 3). Prostaglandins and leukotrienes can then 
bind to their corresponding receptors in vascular smooth muscle and produce constrictor 
responses. The expression o f mRNA for PLA2, COX and LOX in vascular endothelial 
and smooth muscle cells has been demonstrated by RT-PCR (Ost et al., 1998).
Role o f PLA2t COX and 5-LOX in Muscarinic Receptor-Mediated Vasoconstriction
Linkage o f m3 muscarinic receptors to PLA2-activated arachidonic acid release 
has been demonstrated in transfection experiments (Conklin et al., 1988). Moreover, 
cholinergic stimulation or administration of ACh causes prostaglandin synthesis in 
various tissues, including heart (Jaiswal and Malik, 1988) and coronary vascular 
endothelium (Revtyak et al., 1988). LTD4, a metabolite from the 5-LOX pathway, has 
high constrictor potency and can also be produced by coronary arteries (Piper et al.,
1983). According to an observation by Yang et al. (1993), released TxA2 appears to 
modulate the effect o f ACh on the coronary beds in spontaneously beating rat hearts, as 
both the COX inhibitor indomethacin and the TxA2-endoperoxide receptor antagonist SQ 
29548 decrease the ACh-induced vasoconstriction. Recently, it was reported that ACh 
could elicit an endothelium-dependent constriction in rabbit coronary arteries which was 
possibly due to LTD4 (Jino et al., 1996). Based on these data, mediators in the PLA2
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signaling pathway might contribute to the muscarinic receptor-mediated coronary 
vasoconstriction.
Significance
Rat coronary vessels are not unique in having a predominant vasoconstrictor 
response to ACh, since porcine coronary arteries also produce contractile responses upon 
muscarinic receptor activation, even in the presence o f functional endothelium (Graser et 
al., 1986). In addition, intracoronary administration of ACh to human coronary arteries 
causes a vasoconstriction (Horio et al., 1988). Muscarinic receptors in the medial smooth 
muscle appear to be predominant in small coronary vessels from human as well (Angus et 
al., 1991). Thus, the perfused rat heart is a valid model to explore the cholinergic 
mechanisms in coronary resistance vessels.
Clinical studies have provided the foundation for recognition o f the relevance of 
cholinergic mechanisms to the pathogenesis o f vasospasm (Yasue et al., 1986). Coronary 
vasospasm most commonly occurs when vagal tone is high (Kalsner,1989), and plays a 
very important role in a wide variety o f ischemic heart diseases, not only in variant 
angina but also in unstable angina, myocardial infarction, ventricular arrthymias and 
sudden death (Fuster et al., 1992). However, the signaling mechanism o f vasospasm has 
not yet been well defined, and its elucidation remains an important clinical issue. In 
addition, the spasmogenic nature of human coronary arteries in response to ACh is quite 
important for predicting the development o f coronary arterial diseases. Therefore, the 
potential role o f cholinergic mechanisms in coronary vasospasm provides a strong
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rationale for investigating signaling mechanisms for the muscarinic receptor-mediated 
vasoconstriction. A better understanding o f these mechanisms could provide insights 
regarding signaling pathways activated in vasospasm, which will be very valuable in 
developing drugs, preventing vasospasm and improving the therapeutic approaches to 
ischemic heart diseases. The proposed study is undertaken to evaluate the signaling 
mechanisms for the muscarinic receptor-mediated vasoconstriction in rat coronary 
resistance vessels.
Aims
The present study is based on the hypothesis that multiple effector pathways 
contribute to M3 muscarinic receptor-mediated coronary vasoconstriction. To address 
this hypothesis, isolated rat hearts perfused at a constant flow rate are utilized in our 
experiments. Effects o f ACh and the selective muscarinic agonist bethanechol on the 
coronary resistance vessels are quantified by measuring changes in perfusion pressure.
The rat is selected as the experimental model since ACh and bethanechol can produce a 
coronary vasoconstriction in this species as well as in human beings. To elucidate the 
signaling mechanisms for M3 muscarinic receptor-mediated coronary vasoconstriction in 
the isolated rat heart, the following specific aims are proposed:
1. Delineate the mechanisms of Ca2+ supply for bethanechol-mediated coronary 
vasoconstriction.
2. Evaluate the role of PKC in bethanechol-mediated coronary vasoconstriction by 
using the PKC inhibitor chelerythrine.
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3. Examine the role o f  PLA2, COX, LOX and its specific downstream mediators 
generating coronary vasoconstrictor responses to bethanechol.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced 
with 
perm
ission 
of the 
copyright ow
ner. 
Further reproduction 
prohibited 
without perm
ission.
Effects o f  Muscarinic Receptor Activation Elicited by ACh in Coronary Resistance Vessels
Endothelial Cells
Sm ooth M uscle Cells
Cholinergic Nerve Fibers
Fig. 1. Effects of muscarinic receptor activation in coronary resistance vessels. ACh evokes direct 
vasoconstriction by stimulating muscarinic receptors located in smooth muscle layer, In the meantime, 
ACh produces indirect vasodilation and vasoconstriction by stimulating muscarinic receptors located in 
endothelium layer, which are mediated by EDRF, EDHF and EDCF. The overall effect of muscarinic 
receptor activation elicited by ACh depends upon the distribution of muscarinic receptor in both layers.
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Hypothetical Signal Transduction Mechanisms o f  Muscarinic Receptor-Mediated Coronary Vasoconstriction
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Fig. 2. Schematic diagram showing the hypothetical signal transduction mechanisms for muscarinic receptor-mediated 
vasoconstriction in coronary resistance vessels. Abbreviations are: Clca, calcium-dependent chloride channel; MR, muscarinic 
receptor; SR, sarcoplasmic reticulum; Ry, ryanodine receptor; R, IP3-sensitive receptor; CICR, calcium induced calcium 
release; MLC20, 20 kDa myosin light chain; MLCPase, myosin light chain phosphatase; CD, caldesmon; CP, calponin. (UU\
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Signaling Mechanisms for Muscarinic Receptor-Mediated Coronary 
Vasoconstriction in Endothelial and Smooth M uscle Cells
Cholinergic agoninsts Cholinergic agonlnsts
Ca2+ V  Ca2+ Ca2+ V  Ca2+
t a M t e p M i l ls.
Jp if»-vH *\tj^ji.tci^r».K .r.tiiprtsscf.vhV >Jv^;:rsV ;r.ti'' - T 's ' . n t
T-? K 5-Vrr^ :=•'
r^JrrF^ ;^
rtT^Tj-4ifU r:?rJ' .: /'« .*» irv'Tr.yiH
asiifeg
»!>:f.'
TxA2 & PGs
i l l l l B f i i l *
atns&PIMSMSBB
tllif
Iffllppiiiiiilli
Fig. 3. The signaling mechanisms for muscarinic receptor-mediated vasoconstriction in endothelial and smooth muscle cells. 
Abbreviations are: AA, arachidonic acid; G, G protein; LTR, leukotriene receptor; LTs, leukotrienes; MR, muscarinic 
receptor; PC, phosphatidylcholine; PGs, prostaglandins; TPR, TxA2 receptor.
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CHAPTER 2 
MATERIALS AND METHODS
Experimental Animals 
The protocol for this study was approved by the East Tennessee State University 
Committee on Animal Care. Male Sprague-Dawley rats (250-350 g) were used in the 
present study. All rats received humane care in accordance with the Guide for the Care 
and Use o f Laboratory Animals published by the US National Institutes o f Health (NIH 
publications’ No. 8523, revised 1985). The rats were fed a laboratory chow diet, allowed 
free access to tap water and acclimated in a quarantine room for at least one week before 
the experiments.
Isolated Heart Preparation 
Male Sprague-Dawley rats were pretreated with heparin (500 U/100 g body 
weight, i.p.) approximately 20 min before undergoing decapitation while deeply 
anesthetized with sodium pentobarbital (68 mg/kg body weight, i.p.). The heart was 
rapidly removed and placed into a Petri dish containing ice-cold perfusion buffer to 
enable cannulation of the ascending aorta. After flushing the heart with 5 ml ice-cold 
buffer, it was immediately transferred to an isolated heart apparatus for retrograde 
perfusion by the modified Langendorff technique (Broadley, 1979). The non­
recirculating perfusion solution was a modified Krebs-Ringer bicarbonate buffer (pH 
7.35-7.4) containing (in mM): 127.2 NaCl, 4.7 KC1, 2.5 CaCl2, 1.2 KH2P 0 4, 24.9 
NaHC03, 5.5 dextrose, 2.0 sodium pyruvate, 1.2 M gS04 and 0.1% bovine serum
27
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albumin. Perfusion buffers in the reservoir were continuously gassed with 95% 0 2-5% 
C 02. A Masterflex peristaltic pump (Cole Parmer, St. Louis, MO) was used to perfuse 
hearts at a constant flow rate of 8 ml/min. Since the perfusion buffer was conducted into 
the coronary vasculature at a fixed flow rate, changes in perfusion pressure reflect 
changes in coronary vascular resistance, an increase signifying vasoconstriction and a 
decrease vasodilation. To maintain the temperature at 37° C, the buffer passed through a 
water-heated glass coil and the heart was surrounded by a water-heated glass jacket. 
Perfusion pressure, as an indicator o f coronary vascular resistance, was measured by a 
Statham-Gould P23ID pressure transducer (Gould, Cleveland, OH) that was attached to 
the sidearm o f a three-way stopcock located at the proximal end of the aortic cannula. 
Output from the pressure transducer was sent to a Gould 2400S recorder (Gould, 
Cleveland, OH) for monitoring the corresponding change in perfusion pressure.
Administration of ACh and Bethanechol 
ACh and/or bethanechol were administrated by bolus injection (100 pi) or 
constant infusion (100 pl/min) through a short length o f polyethylene 20 tubing (Clay 
Adams, Parsippany, NJ) that emptied into the perfusion buffer at a point close to the 
three-way stopcock attached to the aortic cannula. A  volume of 100 pi for bolus injection 
was given over approximately 2-3 seconds. Serial bolus injections o f ACh or 
bethanechol were made in order o f ascending dose. The interval between ACh bolus 
injections was 5 min. The next dose o f bethanechol was given as soon as the perfusion 
pressure response to the previous dose came back to the baseline. Bethanechol was 
infused into the perfusate at the injection site by a Harvard syringe infusion pump
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(Harvard Apparatus, South Natick, MA).
Experimental Protocols
After a 25-min equilibration period with normal buffer, perfusion was switched to 
a modified buffer containing 20 mM KC1 for the remainder o f the experiment. High K7 
buffer perfusion stopped the heart from beating and gradually increased baseline 
perfusion pressure throughout the experiment. Administration of ACh or bethanechol 
was started after perfusion o f the heart with high K+ buffer for 30 min.
Bolus Injection Study Several doses o f ACh (10, 32, 100, 320 pmol, 1, 3.2, 10, 
32, 100 nmol) were given to obtain dose-response data in KCl-arrested rat hearts. The 
effects of serial bolus injections o f bethanechol (100, 320 pmol, 1, 3.2, 10, 32, 100, 178 
and 320 nmol) were also examined in non-beating rat hearts. Two sets o f dose-response 
data for ACh or bethanechol were collected from each heart preparation. The specific 
inhibitors or blockers were utilized to evaluate signaling mechanisms for the bethanechol- 
evoked coronary vasoconstriction. To further investigate if  the time factor affected the 
effect of specific inhibitors or blockers on the responses to bethanechol and to test i f  the 
inhibitory effect could be reversed, two study protocols were applied: (1) Serial bolus 
injections o f bethanechol were given to obtain the first set of dose-response data as a 
control. The second set of dose-response data were collected 30 min after continuing 
perfusion o f the heart with a  drug-free buffer or after switching to a buffer containing a 
specific inhibitor or blocker. (2) The first set of dose-response data for bethanechol were 
obtained with an inhibitor or a blocker present. After switching to a drug-free buffer for 
30 min, the second set o f dose-response data were collected. Each inhibitor or inhibitor
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combination was evaluated in a separate group of hearts. The study protocols are 
diagramed as in Fig. 4A.
Constant Infusion Study Effects o f infusing bethanechol alone and co-infusing 
nifedipine, SK&F 96365 or chelerythrine were examined in non-beating rat hearts. Each 
inhibitor was assessed in a separate group o f hearts. The study protocol is shown as in 
Fig. 4B.
Preparation of Modified Buffer Solutions 
The 20 mM KC1 buffer solution was made by replacing NaCl with an equimolar 
concentration of KC1 to maintain isotonicity. Ca2+-free buffer solutions were prepared 
by omission o f CaCl2 and addition of EGTA (1 mM). The effect of EGTA is to chelate 
extracellular Ca2+ but not intracellular Ca2+ (Katsuyama, et al., 1991).
Drugs and Sources
The following drugs were used: ACh chloride, A-9-C, bethanechol chloride, L- 
NAME and p-BPB (Sigma Chemical Co., St. Louis, MO); chelerythrine chloride, 
indomethacin, nifedipine and SQ 29548 (Research Biochemicals International, Narick, 
MA); esculetin, LTD4, SK&F 96365 and U 46619 (Biomol Research Laboratories, Inc., 
Plymouth Meeting, PA); L 660711 (a generous gift from Merck Frosst Canada Inc.,
Pointe Claire-Dorval, Quebec, Canada).
Preparation and Storage of Drug Solutions 
ACh and bethanechol were dissolved and diluted in saline; chelerythrine, L-
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NAME, L 660711 and SK&F 96365 were dissolved in distilled water; A-9-C, LTD4 and 
U 46619 were dissolved in ethanol. The final concentration o f ethanol was less than 1%; 
esculetin, indomethacin, nifedipine, p-BPB and SQ 29548 were dissolved in DMSO. The 
final concentration o f DMSO was 0.01%. All stock solutions, except LTD4 (10 pM in 
ethanol), SQ 29548 (10 mM in DMSO) and U 46619 (29 mM in ethanol) were prepared 
freshly for daily use. Aliquots o f LTD4, SQ 29548 and U 46619 stock solutions were 
stored at -80° C. Saline was used to make a series o f dilutions. The specific inhibitors, 
blockers and agonists are summarized in table 1 with their function and the amounts 
applied in this study. The concentration o f a drug administered to the heart by the 
infusion pump was expressed as final molar concentration (M) in the perfusate. The 
quantity o f a drug administrated by bolus injection was expressed as molar weight (mol).
Statistical Analysis
The ACh or bethanechol-elicited changes in perfusion pressure were determined 
relative to baseline values immediately before each bolus injection or constant infusion. 
Dose-response values for each heart were fit with a sigmoidal curve with variable slope to 
obtain estimates o f EDS0, a slope coefficient and maximal vasoconstriction by GraphPad 
Prism version 2.01 (Graphpad software, San Diego, CA). Data were analyzed by 
Microsoft Excel version 7.0a (Microsoft Excel software, Redmond, WA) and the values 
obtained were expressed as arithmetic mean ± SE or geometric mean with 95% 
confidence interval. Values for ED50 were log-transformed for statistical analysis. The 
maximal vasoconstriction, EDS0 and a curve steepness coefficient for ACh and 
bethanechol were compared by unpaired t-test in each group. The maximal
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vasoconstrictor responses and the estimated parameters for two sets o f dose-response 
curves for bethanechol in each heart preparation were compared by paired t-test in each 
group. Two-factor ANOVA with repeated measures was used for evaluation o f baseline 
perfusion pressure data. One-factor ANOVA was utilized to assess the baseline values in 
each column in table 3. Dose-dependent vasoconstrictor responses to bethanechol were 
evaluated by three-factor ANOVA with multiple measures to assess the difference 
between the dose-response curves for control and inhibitor-treatment sets. Post hoc 
comparisons were made by using the Newman-Keuls procedures (NCSS97, Kaysville, 
UT). A probability level o f 0.05 or smaller was considered as significantly different and 
required rejection o f the null hypothesis.
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Experimental Study Protocols for Bolus Injection and Constant Infusion o f  Bethanechol
A.
(1).
■Equilibration with normal buffer for 25. 
min
Perfuse with high K+ buffer for 30 min 
Collect D-R for bethanechol
Trial 1
Perfuse with high K+ buffer 
containing specific inhibitor 
for 30 min 
Collect D-R for bethanechol
Trial2
(2 ).
Equilibration with normal buffer for 25 
min
Perfuse with high K+ buffer 
containing specific inhibitor 
for 30 min 
Collect D-R for bethanechol
Perfuse with high K+ buffer for 30 min 
Collect D-R for bethanechol
Trial 1 Trial2
B.
Bethanechol infusion (32 nmol/100 pl/min)
On
0 min
^  Co-infusion of specific inhibitor ^
at 100 ul/min 
On Off
3 min 6 min
Off
10 min
Fig. 4. Experimental protocols for (A) bolus injection study (B) constant infusion study of 
bethanechol. D-R stands for dose-response data. u>U>
CHAPTER 3
RESULTS
Control Responses to Cholinergic Agonists in KCI-Arrested Hearts 
Bolus injections o f the nonselective cholinergic agonist ACh and the selective 
muscarinic agonist bethanechol produced a dose-dependent vasoconstriction and a 
sigmoidal dose-response curve (Fig. 5). ACh had a higher potency and efficacy than 
bethanechol. The ED50 for bethanechol was 20-fold greater than that for ACh. Dose- 
response parameters for vasoconstrictor responses to these two cholinergic agonists are 
summarized in table 2.
Control Responses to Bethanechol in Spontaneously Beating and KCI-Arrested Hearts 
The vasoconstrictor effects of bolus injections of bethanechol were examined in 
both spontaneously beating and KCl-arrested hearts. As shown in Fig. 6, perfusion of the 
heart with a high K+ buffer caused a leftward shift o f dose-response curve and a larger 
maximal vasoconstriction. The sensitivity of coronary vessels to bethanechol as 
indicated by ED50 was increased about 3-fold (Table 2).
Baseline Perfusion Pressure in KCI-Arrested Hearts 
Baseline perfusion pressure values from experiments in which serial bolus 
injections o f bethanechol were given in the absence and presence o f specific inhibitors or 
blockers are summarized in table 3. Statistical evaluation of these data by two-factor 
ANOVA with repeated measures demonstrated significant increases in baseline perfusion
34
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pressure over the time o f experiments (F I g4 = 454.5, P < 0.001 for trial 1 dose-response 
curve; F ug4 = 449.3, P < 0.001 for trial 2 dose-response curve). Even though means for 
baseline perfusion pressure varied somewhat between groups, the differences in 
magnitude were relatively small. All group means were within a standard deviation o f 
the mean determined for all similar baseline values (referred to each column in table 3). 
Comparison o f baseline perfusion pressure data for the third column in table 3 by one- 
factor ANOVA demonstrated that treatment of hearts with these inhibitors or blockers 
had no significant effect on baseline perfusion pressure (F 9 42 = 0.79, P =  0.62).
Control Responses to Bethanechol 
As shown in the left panel o f Fig. 7A, bolus injection of saline produced a small 
injection artifact in the perfusion pressure recorder tracing. In contrast, bolus injection o f 
32 nmol bethanechol caused a phasic vasoconstriction evidenced by a significant increase 
in perfusion pressure (42 ± I mm Hg, n = 80), which was easily distinguished from the 
injection artifact (Fig. 7A, the right panel).
Under the control condition, sigmoidal dose-response curves for serial bolus 
injections of bethanechol were obtained in trial 1 and trial 2 (Fig. 8). These two dose- 
response curves for bethanechol in the same heart preparation demonstrated a very good 
replication, which provided the basis for a paired design in our subsequent experiments.
Constant infusion of bethanechol at 32 nmol/100 pl/min for 10 min induced a 
tonic vasoconstriction (i.e., a perfusion pressure increase o f 20 ± 1 mm Hg, n = 34) with 
no sign of receptor desensitization (Fig. 7B). A similar but much larger tonic 
vasoconstriction (i.e., a perfusion pressure increase o f 44 ± 1 mm Hg, n =  12, not shown)
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was produced by infusion of bethanechol at 100 nmol/100 pl/min for 10 min. 
Accordingly, the tonic vasoconstriction evoked by infused bethanechol displayed dose 
dependence without tachyphylaxis.
Effect of F.xfracellular Ca2+ on Responses to Bolus Injections o f Bethanechol 
The vasoconstrictor responses to bolus injections of bethanechol were completely 
eliminated by perfusion with Ca2+-ffee buffer in trial 2 (Fig. 9, n = 6). Baseline perfusion 
pressure was rapidly decreased by 14 ± 4 mm Hg after switching the perfusion buffer to a 
Ca2l"-free solution.
Effect of A-9-C on Responses to Bolus Injections o f  Bethanechol 
The Ca2+-dependent Cl'-channel blocker, A-9-C (l mM) significantly reduced the 
bethanechol-evoked vasoconstriction when present in trial 2. The maximal change in 
perfusion pressure elicited by bethanechol was decreased by 3 i ±  l% , 7 l ± 2  mm Hg for 
control compared to 50 ± l mm Hg for A-9-C (Fig. 10). Baseline perfusion pressure was 
initially dropped by 5 ± l mm Hg and gradually returned to the original value during 
continued perfusion with an A-9-C containing buffer.
Effect of Nifedipine on Responses to Bethanechol 
Multiple bolus injections o f 32 nmol bethanechol were administrated when 
different concentrations of the L-type VOCC blocker nifedipine were being infused into 
the perfusion system. The dose-response curve for the inhibitory effect of nifedipine on 
the bethanechol-evoked vasoconstriction was constructed (Fig. 11 A). The
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vasoconstrictor response to 32 nmol bethanechol in the absence of nifedipine was 
considered as a control. The bethanechol-induced vasoconstriction was inhibited by 
nifedipine in a dose-dependent manner and the IC50 was 14.5 nM with 95% confidence 
interval from 9.7 nM to 21.7 nM. Nifedipine reduced the vasoconstrictor response to 
bethanechol by a maximum of 78 ± 3%. Based on this dose-response data for nifedipine, 
the effects o f 3.2, 10 and 32 pM nifedipine on the dose-response relationship for 
bethanechol were studied. The results from perfusion of the hearts with 3.2 and 32 pM 
nifedipine in trial 2 were summarized in table 4.
When nifedipine (10 pM) was present in trial 2 for bolus injections of 
bethanechol, the maximal vasoconstriction was reduced by 59 ± 2% and changed from 79 
± 7 mm Hg to 32 ± 3 mm Hg (Fig. 12A, n = 4). Baseline perfusion pressure was rapidly 
decreased by 13 ± 2 mm Hg and gradually returned to the initial value over a 20 min 
period. Evaluation of the perfusion pressure data by three-factor ANOVA with repeated 
measures, showed that the bethanechol-induced vasoconstriction was dramatically 
suppressed bylO pM nifedipine (F I 72= 9750, P < 0.001). Paired t-tests further 
demonstrated that nifedipine markedly decreased the maximal vasoconstriction to 
bethanechol (t = 9.82, P < 0.01), and caused 3-fold increases of EDS0 (t = 3.37, P = 0.04) 
without changing curve steepness coefficient (t = 0.08, P = 0.94). When nifedipine (10 
pM) was present in trial 1, the maximal vasoconstriction caused by bolus injections of 
bethanechol was 21 ± 2  mm Hg (n = 3). As shown in Fig. 12B, the inhibitory effect of 
nifedipine on the bethanechol-evoked vasoconstriction could not be reversed on a 
washout (three-factor ANOVA for perfusion pressure data, F , 54= 27.04, P = 0.054).
The effect of nifedipine on tonic vasoconstriction to bethanechol was also
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examined. The bethanechol-induced tonic vasoconstriction (i.e., a perfusion pressure 
increase o f 19 ± 0.4 mm Hg, n = 7) was rapidly converted into vasodilation (i.e., a 
perfusion pressure decrease o f 17 ±  1 mm Hg) by the simultaneous infusion of nifedipine 
(10 pM final concentration). Even after stopping the co-infusion o f  nifedipine, continued 
infusion o f bethanechol could not evoke any vascular response. Typical recorder tracings 
showing the effects o f nifedipine and 0.1% DMSO vehicle on the response to infused 
bethanechol are presented in Fig. 13A and 13B.
F.ffect o f SK&F 96365 on Responses to Bethanechol 
Multiple bolus injections o f 32 nmol bethanechol were given while different 
concentrations o f SK&F 96365 were being infused into the perfusion system, and the 
dose-response curve for SK&F 96365 was obtained (Fig. 1 IB). The vasoconstriction to 
32 nmol bethanechol in the absence of SK&F 96365 was considered as a standard. 
Bethanechol-evoked vasoconstrictor responses were dose-dependently inhibited by 
SK&F 96365. The IC50 caused by SK&F 96365 was 2.2 pM with 95% confidence 
interval from 1.8 pM to 2.8 pM. According to this basic dose-response curve, 10 pM 
SK&F 96365 could entirely eliminate the bethanechol-produced vasoconstriction in KCl- 
arrested rat hearts.
The effect of SK&F 96365 (10 pM) on the vasoconstriction produced by 
bethanechol was investigated in this study. Vasoconstrictor responses to bolus injections 
of bethanechol were completely converted into vasodilations when SK&F 96365 was 
present in trial 2 (Fig. 14A). The maximal change in perfusion pressure caused by 
bethanechol was substantially altered from an increase of 65 ± 2 mm Hg to a decrease of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
39
15 ±  4 mm Hg (paired t-test, t = 11.74, P <  0.001). It was also demonstrated that SK&F 
96365 dramatically abolished the bethanechol-elicited vasoconstriction by evaluation of 
the perfusion pressure data by three-factor ANOVA with repeated measures (F 172 = 77,
P < 0.001). When SK&F 96356 (10 pM) was present in trial 1, bolus injections of 
bethanechol also caused vasodilations and the maximal change in perfusion pressure was 
-10 ±  2 mm Hg (Fig. 14B). The inhibitory effect of SK&F 96356 on the vasoconstrictor 
response to bethanechol could be reversed on a washout (three-factor ANOVA for 
perfusion pressure data, F , 54 = 216, P < 0.01), and the maximal vasoconstriction 
produced by subsequent bolus injections o f bethanechol was 44 ±  1 mm Hg.
To determine whether or not the phasic vasodilation evoked by bethanechol in the 
presence of SK&F 96365 was nitric oxide-dependent, a combination o f SK&F 96365 (10 
pM) and L-NAME (100 pM) was added to the perfusion buffer in trial 2 (Fig. 15, n = 3). 
Since baseline perfusion pressure was considerably increased by 67 ±  6 mm Hg, we 
readjusted it back to the average range for baseline value (76 ± 5 mm Hg) by lowering the 
perfusion flow rate. Bolus injections o f bethanechol still evoked vasodilations under this 
treatment, and the maximal vascular response to bethanechol was converted from a 
vasoconstriction o f 62 ± 3 mm Hg for control, to a vasodilation o f 14 ± 0.3 mm Hg for 
the combination o f SK&F 96365 and L-NAME (paired t-test, t = 30.2, P < 0.001). 
Comparison of dose-response curves for bethanechol between treatment of SK&F 96365 
alone and treatment of a combination o f SK&F 96365 and L-NAME, no significant 
difference was detected (two-factor ANOVA with repeated measures for perfusion 
pressure data, F t 63= 3.57, P = 0.07).
Tonic vasoconstriction caused by infusion of 32 nmol bethanechol was rapidly
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converted into vasodilation by the simultaneous infusion of SK&F 96365 (10 pM final 
concentration). The corresponding change in perfusion pressure was altered from 20 ±
0.8 mm Hg to -6 ± 1 mm Hg (n = 10). After terminating the co-infusion o f SK&F 
96365, continued infusion o f bethanechol immediately produced a greater tonic 
vasoconstriction (i.e., a perfusion pressure increase o f 43 ± 3 mm Hg). Compared to the 
original baseline value (51 ±  1 mm Hg), the new baseline perfusion pressure reached a 
higher level (65 ±  3 mm Hg) after stopping infused bethanechol. A typical recorder 
tracing for the concomitant infusion o f SK&F 96365 with bethanechol is shown in Fig. 
13C.
Effect o f a Combination o f Nifedipine and SK&F 96365 on Responses to Bolus
Injections o f  Bethanechol 
The vasoconstrictor responses to bolus injections of bethanechol were almost 
abolished by perfusion o f the heart with a buffer containing a combination o f nifedipine 
(10 pM) and SK&F 96365 (10 pM) in trial 2 (Fig. 16). Under this condition, the peak 
vasoconstriction was greatly decreased by 87 ± 2% and changed from 71 ±  2 mm Hg to 9 
± 1 mm Hg (paired t-test, t = 22.97, P < 0.001).
Effect of Chelerythrine on Responses to Bethanechol 
When chelerythrine (5 pM) was present in trial 2 (Fig. 17A), the maximal 
vasoconstriction to bethanechol was reduced by 78 ± 2% and lowered from 62 ± 3  mm 
Hg to 13 ±  1 mm Hg (paired t-test, t = 15.49, P < 0.0001). Baseline perfusion pressure 
was initially decreased by 5 ±  0.3 mm Hg in the presence of chelerythrine but gradually
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returned to the original baseline value before the first injection of bethanechol. A 
significant inhibitory effect o f chelerythrine on the response to bethanechol was detected 
when perfusion pressure data were evaluated by three-factor ANOVA with repeated 
measures (F , 10g = 150, P < 0.001). Paired t-test demonstrated that chelerythrine had no 
effect on EDS0 for the bethanechol-induced vasoconstriction (t = 1.68, P = 0.154). When 
chelerythrine was present in trial 1, the maximal increase in perfusion pressure for 
bethanechol was 11 ±  2 mm Hg. As shown in Fig. 17B, the inhibitory effect of 
chelerythrine on the bethanechol-produced vasoconstriction could not be reversed on a 
washout (three-factor ANOVA for perfusion pressure data, F j 90= 5.07, P = 0.09).
Tonic vasoconstriction produced by infusion o f 32 nmol bethanechol was 
gradually attenuated from 22 ±  1 mm Hg to 5 ± 1 mm Hg (n =  9) by the concomitant 
infusion of chelerythrine (5 pM final concentration). Baseline perfusion pressure before 
infusion of bethanechol was 68 ± 1 mm Hg. After stopping the co-infusion of 
chelerythrine, continued infusion of bethanechol gradually produced a much smaller tonic 
vasoconstriction (i.e., perfusion pressure increase of 11 ± 1 mm Hg). A typical recorder 
tracing of this response pattern is shown in Fig. 18 A.
In some rat hearts, the tonic vasoconstriction to infused bethanechol (i.e., a 
perfusion pressure increase o f 19 ± 1 mm Hg) was even converted into vasodilation (i.e., 
a perfusion pressure decrease o f 6 ± 1 mm Hg) by the co-infusion o f chelerythrine (n =
8). Baseline perfusion pressure before infusion of bethanechol was 78 ± 2 mm Hg for 
this group of hearts. Continued infusion of bethanechol gradually brought perfusion 
pressure back to the baseline after stopping the co-infusion o f chelerythrine. The new 
baseline perfusion pressure dropped to a lower value (66 ± 1 mm Hg) when infusion of
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bethanechol was discontinued. A typical recorder tracing from this group is shown in 
Fig. 18B.
Effects o f p-BPB. Indomethacin and Esculetin on Responses to Bolus Injections of
Bethanechol
When present in trial 2, p-BPB (5 pM) decreased the maximal vasoconstrictor 
response to bolus injections of bethanechol by 43 ±  3%, while indomethacin (10 pM) 
and esculetin (10 pM) reduced this effect by 31 ± 2%  and 30 ± 1%, respectively (Table 5, 
Fig. 19). Evaluation o f these dose-dependent perfusion pressure data by three-factor 
ANOVA with repeated measures indicated that all inhibitors significantly decreased the 
bethanechol-evoked vasoconstriction (p-BPB : F u90= 93, P < 0.001; indomethacin : F U72 
= 129, P = 0.001; esculetin : F , 72= 13, P = 0.037). Paired t-test demonstrated that none 
o f these inhibitors impacted the ED50 of bethanechol (p-BPB : t = -2.18, P = 0.09; 
indomethacin : t = -1.23, P = 0.31; esculetin : t=  -0.15, P = 0.89). Perfusion o f the heart 
with a combination o f  indomethacin and esculetin in trial 2 did not produce further 
inhibition (n = 3, not shown). When indomethacin or esculetin was present in trial 1, no 
inhibitory effect on the vasoconstrictor response to bolus injections of bethanechol was 
observed (n = 3 for each, not shown).
Effect o f SQ 29548 on Responses to Bethanechol 
The TxA2 analogue U 46619 dose-dependently produced a vasoconstriction in rat 
coronary resistance vessels, and the peak response was 68 ±  6 mm Hg (Fig. 20A). U 
46619-evoked vasoconstriction was completely eliminated by the specific TxA2 receptor
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antagonist SQ 29548 (1 fiM, n = 3, not shown). The effect o f  SQ 29548 in trial 2 on the 
response to bolus injections o f bethanechol was examined in isolated non-beating rat 
hearts (Table 5). The maximal vasoconstrictor response to bethanechol was significantly 
decreased by 16 ± 1% (paired t-test, t = 11, P < 0.01). A significant inhibition on the 
response to bethanechol caused by SQ 2548 was detected when evaluating the perfusion 
pressure data by three-factor ANOVA with repeated measures (F , 54 = 38, P = 0.03). In 
the meantime, paired t-test showed that SQ 29548 did not change the ED50 of bethanechol 
(t = 0.05, P = 0.10). When SQ 29548 was present in trial 1, the inhibitory effect on the 
bethanechol-induced vasoconstriction was not found (n = 3, not shown). Infusion o f SQ 
29548 (1 pM final concentration) did not exert any influence on the tonic 
vasoconstriction produced by infused bethanechol (n = 3, not shown).
Effect o f L 660711 on Responses to Bethanechol 
In isolated non-beating rat hearts, serial bolus injections o f  LTD4 caused a dose- 
dependent vasoconstriction with a maximal perfusion pressure increase of 74 ± 0.4 mm 
Hg (Fig. 20B). LTD4-induced vasoconstriction was abolished by the selective LTD4 
receptor antagonist L 660711 (10 pM, n = 3, not shown), which had no effect on 
perfusion pressure by itself. The maximal vasoconstrictor response to bolus injections of 
bethanechol was reduced by 20 ± 4% with L 660711 present in trial 2 (paired t-test, t = 
4.58, P = 0.04; Table 5). Evaluation of these dose-dependent perfusion pressure data by 
three-factor ANOVA with repeated measures showed that the effect o f L 660711 on the 
bethanechol-produced vasoconstriction was significant (F 154 = 135, P < 0.001). Paired 
t-test showed that the EDS0 o f bethanechol was not changed by L 660711 (t = -2.3, P =
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0.15). When L 660711 was present in trial 1, this inhibitory effect on the vasoconstrictor 
response to bethanechol was not observed (n = 3, not shown). Likewise, the concomitant 
infusion o f L 660711 (10 pM final concentration) did not affect the bethanechol-induced 
tonic vasoconstriction at all (n = 3, not shown).
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Comparison o f  A C h- and Bethanechol-Evoked D ose-D ependent 
Phasic V asoconstriction in KCI-Arrested Hearts
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Fig. 5. Dose-response curves for coronary vasoconstrictor effects 
o f  ACh and bethanechol in KCl-arrested isolated rat hearts.
Perfusion pressure data were obtained from separate groups (n = 6 
for each agonist). The points in graph represent means and vertical 
bars represent the SEs. Statistical evaluation o f perfusion pressure 
data by two-factor ANOVA with repeated measures demonstrated the 
dose-response curve for ACh was significantly different from that 
for bethanechol (F ^ 10§ = 24.37, P < 0.0001). Unpaired t-tests on 
the maximal vasoconstriction, ED50 and curve steepness coefficient 
o f dose-response curves for ACh and bethanechol further indicated 
that there was a significant difference between these two curves (for 
maximal vasoconstriction: t = 2.96, P = 0.01; for ED50: t =  6.27, P < 
0.0001; for curve steepness coefficient: t = 2.54 , P = 0.03).
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Com parison o f  Bethanechol-Evoked Phasic V asoconstriction  
in Spontaneously Beating and KCI-Arrested H earts
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*  Non-beating Hearts
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Fig. 6. Dose-response curves for coronary vasoconstrictor effects o f 
bethanechol in beating and non-beating hearts. Perfusion pressure data 
were obtained from separate groups, n = 3 for beating hearts and n = 6 
for non-beating hearts. The points in graph represent means and vertical 
bars represent the SEs. Statistical evaluation o f perfusion pressure data 
by two-factor ANOVA with repeated measures demonstrated the 
dose-response curve for bethanechol in beating hearts was significantly 
different from that in non-beating hearts (F 8i = 60.83, P < 0.0001). 
Unpaired t-tests on the maximal vasoconstriction, ED50 and curve 
steepness coefficient for dose-response curves for bethanechol further 
indicated that there was a significant difference between these two 
curves (for maximal vasoconstriction, t = 4.15, P = 0.004; fo r ED5q: t = 
7.51, P = 0.0001; for curve steepness coefficient: t = 2.64 , P = 0.03).
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Typical Recorder Tracings for Bethanechol-induced Phasic  
and Tonic Vasoconstriction
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Fig. 7. Typical recorder tracings showing the effects o f (A) bolus injections of 
saline and bethanechol and (B) infusion of bethanechol on perfusion pressure 
in KCl-arrested isolated rat hearts. Bolus injections and infusions are indicated 
by arrows.
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D uplicate Control D ose-R esponse Curves for B olus  
Injections o f  Bethanechol
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Fig. 8. Duplicate dose-response curves for coronary vasoconstrictor 
effect o f  bethanechol in KCl-arrested isolated rat hearts (n = 6). The 
points in graph represent means and vertical bars represent the SEs. 
Statistical evaluation of perfusion pressure data by three-factor 
ANOVA with repeated measures demonstrated that the time factor 
did not have a significant effect on the dose-dependent responses to 
bethanechol (F lt IOs = 7.27, P = 0.054). Paired t-tests on the 
maximal vasoconstriction, ED50 and curve steepness coefficient o f 
dose-response curves for bethanechol in trial 1 and trial 2 further 
indicated that there was no significant difference between these two 
curves (for the maximal vasoconstriction: t = 0.04, P = 0.97; for 
ED50: t =  1.45, P = 0.21; for curve steepness coefficient: t = -0.23 ,
P = 0.83).
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Effect o f  Extracellular Ca2+ on  Phasic V asoconstriction Produced  
by B olus Injections o f  Bethanechol
75p ■ Trial 1 (Control) 
Trial 2 (Ca2+-free)
-10 -9 -8 -7
Log Bethanechol Dose (mol)
I
Fig. 9. Effect o f  extracellular Ca on dose-response curve for 
coronary vasoconstrictor action o f bethanechol in KCl-arrested 
isolated rat hearts. The curves were constructed by computerized 
analysis o f  data from 6 hearts. The points in graph represent means 
and vertical bars represent the SEs.
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Effect o f  A -9-C  on Bethanechol-Elicited Phasic V asoconstriction
75-| ■ Trial 1 (Control)
a Trial 2 (1 mM A-9-C)
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Fig. 10. Effect o f  A-9-C on dose-response curve for coronary 
vasoconstrictor action o f bethanechol in KCl-arrested isolated rat hearts 
(n = 3). The points in graph represent means and vertical bars represent 
the SEs. Evaluation o f  the perfusion pressure data by three-factor 
ANOVA with repeated measures, revealed that A-9-C exerted a significant 
inhibition on bethanechol-elicited vasoconstriction (F [ 54 = 55.18, P <  
0.001). Paired t-test demonstrated that A-9-C had no effect on ED50 and 
curve steepness coefficient for bethanechol-causedvasoconstricton(for 
ED50: t = 1.90, P = 0.20; for curve steepness coefficient: t = 1.09, P = 
0.39), but caused a significant decrease in the maximal vasoconstriction 
induced by bethanechol (t = 15.37, P = 0.004).
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D ose-R esponse Curves for Inhibitory E ffects o f  N ifedipine  
and SK& F 96365 on 32 nm ol B ethanechol-Evoked Vasoconstriction
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Fig. 11. Dose-response curves for inhibitory effects o f (A) nifedipine 
and (B) SK&F 96365 on the vasoconstrictor responses to multiple bolus injections 
o f 32 nmol bethanechol in KCl-arrested isolated rat hearts. These two curves 
fitted into the sigmoidal model very well (for nifedipine, r2 = 0.9815; for SK&F 
96365, r2 = 0.9966). The equilibration time between concentrations o f nifedipine 
or SK&F 96365 was 5 min. The curves were obtained by computerized analysis 
o f data from 4 hearts for each. The points in graph represent means and vertical 
bars represent the SEs.
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Effect o f  N ifedipine on Phasic Vasoconstriction C aused  
by Bolus Injections o f  Bethanechol
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Fig. 12. Effect of nifedipine on dose-response curves for coronary vasoconstrictor 
action of bethanechol in KCl-arrested isolated rat hearts when present in (A) trial 2 
and (B) trial 1. The curves were obtained by computerized analysis of data from 4 
hearts for A and 3 hearts for B. The points in graph represent means and vertical 
bars represent the SEs.
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Effects o f  N ifedipine and SK&F 96365  on  
Bethanechol-induced Tonic Vasoconstriction
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Fig. 13. Typical recorder tracings showing the effects o f (A) 0.1 % 
DMSO (B) nifedipine and (C) SK&F 96365 on tonic vasoconstriction 
produced by infusion of bethanechol in KCl-arrested isolated rat hearts. 
Infusions are indicated by arrows.
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E ffect o f  SK&F 96365 on Phasic V asoconstriction  Evoked by  Bolus 
Injections o f  B ethanechol
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Fig. 14. Effect of SK&F 96365 on dose-response curve for coronary 
vasoconstrictor action o f bethanechol in KCl-arrested isolated rat hearts 
when present in (A) trial 2 and (B) trial 1. The curves were obtained by 
computerized analysis of data from 4 hearts for A  and 3 hearts for B. The 
points in graph represent means and vertical bars represent the SEs.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
55
E ffect o f  a Com bination o f  SK& F 96365 and L-N A M E on  
Bethanechol-Produced Phasic Vasoconstriction
■ Trial 1 (Control) 
a Trial 2 (10 pM SK&F 96365 + 100 pM L-NAME)
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Fig. 15. Effect o f  a combination o f  SK&F 96365 and L-NAME on 
dose-response curve for coronary vasoconstrictor action o f  bethanechol 
in KCl-arrested isolated rat hearts (n = 3). The points in graph represent 
means and vertical bars respresnt the SEs.
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Effect o f  a C om bination o f  N ifedipine and SK & F 96365  on 
Bethanechol-Produced Phasic V asoconstriction
■ Trial 1 (Control) 
* Trial 2 (10 pM Nifedipine + 10 pM SK&F 96365)
75-i
50-
25-
-10 •9 611 •8 -7
Log Bethanechol Dose (mol)
Fig. 16. Effect o f  a combination o f nifedipine and SK&F 96365 on 
dose-response curve for coronary vasoconstrictor action o f  
bethanechol in KCl-arrested isolated rat hearts. The curves were 
obtained by computerized analysis o f data from 3 hearts. The points 
in graph represent means and vertical bars represent the SEs.
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Effect o f  Chelerythrine on  Phasic V asoconstriction  E voked by Bolus 
Injections o f  B ethanechol
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Fig. 17. Effect o f chelerythrine on dose-response curves for coronary 
vasoconstrictor action o f  bethanechol in KCl-arrested isolated rat hearts 
when present in (A) trial 2 and (B) trial 1. The curves were obtained by 
computerized analysis o f  data from 6 hearts for A and 5 hearts for B. The 
points in graph represent means and vertical bars represent the SEs.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
58
E ffect o f  Chelerythrine on Tonic Vasoconstriction Evoked  
by Infusion o f  Bethanechol
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Fig. 18. Typical recorder tracings showing the effect o f chelerythrine 
on tonic vasoconstriction produced by infusion o f bethanechol in 
KCl-arrested isolated rat hearts. Infusions are indicated by arrows.
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Bargraph Show ing the Effects o f  p-BPB, Indomethacin, Esculetin, 
SQ 29548 and L 660711 on the M aximal Phasic Vasoconstriction  
Induced by  Bethanechol
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Fig. 19. Effects o f p-BPB (5 pM), indomethacin (10 pM), SQ29548 
(1 pM), esculetin (10 pM) and L 660711 (10 pM) on the maximal 
vasoconstrictor response to bethanechol in KCl-arrested rat hearts. 
Data are presented as arithmetic means with SEs (n = 3-6 for each 
group). Paired t-tests were utilized for comparing the maximal 
vasoconstrictor responses in each group. NS stands for no significant 
difference and * represents significant difference between the 
maximal vasoconstriction for control and treatment trials (P < 0.05).
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D ose-D ependent V asoconstrictor Effects o f  U  4 6 6 1 9  and LTD .
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Fig. 20. Dose-response curves for coronary vasoconstrictor effects o f (A) 
U 46619 and (B) LTD4 in KCl-arrested isolated rat hearts. The curves 
were constructed by computerized analysis o f data from 4 hearts for A 
and 3 hearts for B. The points in graph represent means and vertical bars 
represent the SEs.
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TABLE 1.
Summary o f Specific Inhibitors, Blockers and Agonists Used in the Present Study
Chemical Name Function Concentration or 
Dose Range
A-9-C Ca2+-dependent Cl' channel blocker 1 mM
Chelerythrine PKC inhibitor 5 pM
Esculetin 5-Lipoxygenase inhibitor 10 pM
Indomethacin Cyclooxygenase inhibitor 10 pM
L-NAME Nitric oxide synthase inhibitor 100 pM
l t d 4 LTD4 receptor agonist 0.01-100 pmol
L 660711 LTD4 receptor antagonist 10 pM
Nifedipine Voltage-operated Ca2+ channel blocker 10 pM
p-BPB PLA2 inhibitor 5 pM
SK&F 96365 Receptor-operated Ca2" channel blocker 10 pM
SQ 29548 TxA2 receptor antagonist 1 pM
U 46619 TxA2 analogue 1 pmol-10 nmol
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TABLE 2.
Summary of Dose-Response Parameters for Vasoconstriction to ACh and Bethanechol in 
KCl-arrested and Spontaneously Beating Hearts
Agonist Maximal 
vasoconstriction 
(mm Hg)
ED50 (95% C.I.) nmol Curve steepness 
coefficient
ACh (K) 81 ± 4 1.35 (0.65-2.82) 1.28 ± 0.1
Bethanechol (K) 67 ± 3a 26.92 (12.91-56.1)3 1.73 ± 0.2a
Bethanechol (B) 47 ± l fa 95.5 (33.88-269.2)b 1.13 ± 0.02b
K stands for KCl-arrested hearts, B represents spontaneously beating hearts. Data 
were computerized from 3-6 rat hearts, n equals 6 for ACh (K), n equals 6 for 
Bethanechol (K), n equals 3 for Bethanechol (B). Data for maximal vasoconstriction and 
curve steepness coefficient are expressed as arithmetic mean ± SEs. Data for EDS0 are 
expressed as the geometric mean with 95% confidence interval (C.I.). ED50 and curve 
steepness coefficient are determined from nonlinear regression analysis o f dose-response 
data.
a Significantly different from ACh (K). 
b Significantly different from Bethanechol (K).
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TABLE 3.
Baseline Values for Perfusion Pressure in Experiments with Serial Bolus Injections o f 
Bethanechol in the Absence and Presence o f Specific Inhibitors and Blockers
Treatment
Baseline Perfusion Pressure (mm Hg)
Trial 1 Dose-Response Curve Trial 2 Dose-Response Curve
First Dose Last Dose First Dose Last Dose
Control 47 ±  1 65 ± 2* 74 ± 2 82 ±2*
Chelerythrine 50 ± 2 65 ±2* 74 ± 2 82 ±2*
SK&F 96365 48 ± 2 59 ± 1* 73 ± 3 81 ±3*
A-9-C 55 ± 2 62 ± 1* 73 ± 1 83 ±2*
Nifedipine 48 ± 1 62 ±2* 11 ± 3 90 ± 1*
p-BPB 51 ± 2 63 ±2* 16 ± 2 89 ±2*
Indomethacin 50 ± 4 68 ± 4* 19 ± 5 92 ±5*
Esculetin 52 ± 2 63 ±2* 15 ± 2 88 ± 1*
SQ 29548 53 ± 2 65 ±  1* 11 ± 2 89 ± 1*
L 660711 54 ± 2 66 ± 3* 80 ± 4 89 ± 5*
Values shown were measured before injection of the first dose and the last dose 
administered for trial 1 (control) and trial 2 (treated with an inhibitor or a blocker) dose- 
response curves o f bethanechol. Baseline perfusion pressure data are expressed as mean 
± SEs (n = 3-6 for each group). Mean ± SDs for columns are 50 ± 5 mm Hg (n = 42), 64 
± 5 mm Hg (n = 42), 16 ± 5  mm Hg (n = 42) and 86 ±  6 mm Hg (n = 42). * indicates that 
baseline perfusion pressure for the last dose is significantly different from that for the first 
dose in each dose-response curve.
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TABLE 4.
Effects of 3.2 and 32 pM Nifedipine on Dose-Dependent Vasoconstriction Produced by Serial Bolus Injections of Bethanechol
Treatment 3.2 pM nifedipine (n = 3) 32 pM nifedipine (n = 3)
Trial 1 Trial 2 Trial 1 Trial 2
Initial drop in baseline 
perfusion pressure (mm Hg)
NA 15 ± 1 NA 14 ± 1
Maximal vasoconstriction 
(mm Hg)
74 ±3 31 ± 1* 71 ±5 29 ±2*
Maximal % inhibition NA 58.8 ±0.3 NA 59.5 ±0.3
ED50 (95% C.I.) nmol 28.18(12.88-61.66) 64.57 (53.70-77.62)* 25.70(19.82-33.34) 64.57 (35.48-117.5)*
Curve steepness coefficient 1.58 ± 0.12 1.81 ±0.14 1.65 ±0.23 1.81 ±0.08
Values for baseline perfusion pressure, maximal vasoconstriction, maximal % inhibition and curve steepness coefficient are 
expressed as arithmetic mean ± SEs. Data for ED50 are expressed as geometric mean with 95% confidence interval (C.I.). ED50 and 
curve steepness coefficient are determined from nonlinear regression analysis of dose-response data.
* Significantly different from trial 1 in each treatment group (paired t-test, P < 0.05).
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TABLE 5.
Effects of Enzyme Inhibitors and Receptor Antagonists in the PLA2 Pathway on Dose-Response Parameters for the Bethanechol- 
Evoked Vasoconstriction
Treatment Trial EDj0 (95% C.I.) nmol Curve steepness coefficient Maximal response (mm Hg)
p-BPB 1 20.20(18.27-22.34) 1.53 ±0.06 70 ±4
(n = 5)
2 25.01 (21.88-28.60) 1.40 ±0.07 40 ± 4*
Indomethacin 1 22.90 (20.21-25.96) 1.64 ± 0.17 71 ±2
(n = 4)
2 27.96 (23.04-33.93) 1.36 ±0.02 49 ± 1*
Esculetin 1 30.58 (29.33-31.88) 1.58 ±0.09 72 ±5
(n = 4)
2 32.66 (30.12-35.42) 1.79 ±0.25 50 ±4*
SQ 29548 1 23.80 (21.25-26.65) 1.55 ±0.06 68 ±3
(n = 3)
2 23.43 (20.19-27.19) 1.61 ±0.19 57 ±2*
L 660711 1 27.56(23.08-32.91) 1.46 ±0.25 69 ±2
(n = 3)
2 36.39 (33.38-39.67) 1.32 ±0.02 55 ±2*
1-trial 1 (control), 2-trial 2 (treated with an inhibitor or a blocker), n-number of subjects. Data for ED50 are given as geometric 
means with 95% confidence intervals (C.I.). Curve steepness coefficient and maximal vasoconstrictor response are expressed as 
arithmetic means with SEs. ED50 and curve steepness coefficient are determined from nonlinear regression analysis of dose-response 
data.
* Significantly different from trial 1 in each treatment group (paired t-test, P < 0.05).
ONU\
CHAPTER 4 
DISCUSSION
Our observations in KCl-arrested rat hearts demonstrate that bolus injection of 
bethanechol dose-dependently evokes a phasic contraction o f coronary resistance vessels, 
while infusion o f bethanechol produces a tonic vasoconstriction without receptor 
desensitization. A similar phenomenon o f bethanechol-elicited dose-dependent phasic 
vasoconstrictions was also reported in spontaneously beating rat hearts (Sakai, 1980). 
However, the signaling mechanisms coupling muscarinic receptor-mediated 
vasoconstriction have not yet been well delineated. The present study was undertaken to 
elucidate multiple effector pathways for the contractile function o f rat coronary resistance 
vessels in response to muscarinic agonists. Our major findings are: (1) the bethanechol- 
evoked vasoconstriction is an extracellular Ca2"-dependent process; (!) Ca2+ influx 
through ROCCs and VOCCs are very essential to the bethanechol-induced coronary 
vasoconstrictor effect; (3) PKC plays a pivotal role in the regulation o f contractile 
response to bethanechol; (4) TxA2 and LTD4 released from the PLA2 pathway may 
contribute to the bethanechoi-mediated vasoconstriction but with less significance.
Experimental Model 
The Langendorff heart is a good model to assess the effects o f drugs on coronary 
resistance vessels (Broadley, 1979). However, variations in heart rate, contractility, 
extravascular compression, luminal and transluminal pressure, and myocardial 
metabolism in the spontaneously beating heart introduce complications that make it
66
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difficult to accurately evaluate the direct effect of cholinergic agonists on coronary 
vessels. In addition, cholinergic agonists have potent negative inotropic and chronotropic 
effects on rat myocardium (Sakai, 1980; Loffelholz and Pappano, 1985; Yang et al.,
1993; Hoover and Neely, 1997) which may affect coronary vascular tone secondarily.
For example, decreases in contractility and cardiac oxygen consumption and increases in 
myocardial wall tension are considered to be a cause of coronary vasoconstriction in the 
spontaneously beating heart. Thus, the KCl-arrested heart becomes a suitable model 
which allows examination o f the direct effect o f cholinergic agonists on coronary 
vascular resistance without indirect effects from other factors, such as the mechanical 
influence of cardiac contraction and changes in cardiac metabolism.
Vascular Responses to Cholinergic Agonists 
Bolus injection o f  ACh or bethanechol caused a dose-dependent increase in 
perfusion pressure and a dose-dependent decrease in heart rate in spontaneously beating 
rat hearts. These observations are consistent with the findings o f other investigators 
(Sakai, 1980; Loffelholz and Pappano, 1985; Yang et al., 1993; Hoover and Neely, 1997). 
It might be argued that the vasoconstrictor effect of ACh and bethanechol is an 
autoregulatory response o f coronary vessels to the reduced myocardial Oz demand 
associated with bradycardia rather than a direct coronary vascular effect. Thus, all 
subsequent experiments were conducted in KCl-arrested hearts. The same cholinergic 
agonists still caused coronary vasoconstriction dose-dependently. Bethanechol produced 
a very similar vasoconstrictor response as ACh but with lower potency and efficacy.
These results support the conclusion that ACh and bethanechol both have direct
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vasoconstrictor effects on rat coronary resistance vessels. Since bethanechol can mimic 
the vascular response evoked by the classical cholinergic neurotransmitter ACh and has 
selectivity only for muscarinic receptors, it was utilized as an experimental tool for 
investigating the signaling mechanisms for muscarinic receptor-mediated 
vasoconstriction.
It is noteworthy that the vasoconstrictor response to cholinergic agonists occurs 
even in the presence o f  intact endothelium. A couple of possible mechanisms are 
speculated to be involved: (1) EDRF and/or EDHF released from coronary endothelium 
in response to cholinergic agonists may not be sufficient to cause the overall 
vasorelaxation; (2) the direct vasoconstrictor effect o f cholinergic agonists on coronary 
vascular smooth muscle may override the endothelium-dependent vasodilation; (3) the 
indirect endothelium-dependent vasoconstriction may enhance the overall vasoconstrictor 
responses to cholinergic agonists. Consequently, the vasodilator component in response 
to cholinergic agonists is probably masked by the potent vasoconstrictor component of 
cholinergic agonists in the rat coronary vascular bed.
Effect o f  High FC Perfusion 
KC1 typically induces a sustained contraction of vascular smooth muscle by 
membrane depolarization which initiates Ca2+ influx through voltage-gated Ca2+ channels 
(Shimamoto et al., 1993). Likewise, perfusion with a high K+ buffer in our experiments 
caused a gradual but a significant increase in baseline perfusion pressure. Even though 
baseline perfusion pressure was slowly increased in KCl-arrested hearts, serial bolus 
injections of bethanechol evoked similar vasoconstrictor responses as in spontaneously
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beating hearts. However, there was a leftward shift o f  the dose-response curve for 
bethanechol. The greater potency o f bethanechol in KCl-arrested hearts may reflect the 
interaction between high K+- and bethanechol-induced signaling mechanisms for 
contraction. 20 mM KC1 exposure has been reported to reduce endothelium-dependent 
(EDHF-related) relaxation in porcine and human coronary arteries (He, 1997). High K~ 
perfusion may also directly enhance the sensitivity o f coronary vessels to bethanechol, 
most likely owing to the fact that agonist-mediated Ca2+ entry is superimposed on KC1- 
induced membrane depolarization.
Extracellular Ca2+ and VOCCs in Signaling for Muscarinic-Receptor Mediated
Vasoconstriction
In accordance with the evidence that high K ’’-induced membrane depolarization 
could subsequently open VOCCs and increase basal vascular tone (Shimamoto et al., 
1993), baseline perfusion pressure in our experiments was rapidly reduced by Ca2'-ffee 
medium as well as nifedipine. These results suggest that Ca2+ influx through VOCCs 
contributes to maintenance of basal coronary vascular tone in KCl-arrested hearts. 
Nifedipine was chosen as the L-type VOCC blocker in the present study since it is 
selective only for vascular smooth muscle without any cardiac effect. In addition, other 
L-type VOCC blockers (e.g. verapamil and diltiazem) are reported inhibiting ROCCs at 
higher concentrations (Huang and Ho, 1996).
Vasoconstrictor responses in some smooth muscles are dependent on extracellular 
Ca2+. The entry o f extracellular Ca2+could be required to refill cytosolic Ca2+ stores or to 
regulate the contractile elements directly (Berridge, 1997). In the present study, the
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bethanechol-evoked phasic vasoconstriction was entirely abolished by Ca2+-free buffer. 
Similar results were observed in spontaneously beating rat hearts by others (Nuutinen et 
al., 1985; Su and Narayanan, 1993). Therefore, the Ca2+ source for muscarinic receptor- 
mediated vasoconstriction is suggested to be from extracellular space and Ca2+ influx is 
extremely important for this vascular effect. It is further supported by the finding that 
resistance arteries generally have a much greater dependence on extracellular Ca2+ than 
elastic capacitance vessels (Bulbring and Tomita, 1987). As the arteries get smaller, 
extracellular Ca2+ influx becomes more dominating for vascular smooth muscle 
contraction (Low et al., 1996).
VOCCs are documented to be the predominant Ca2+ entry pathway in vascular 
smooth muscle contraction (Malarkey et al., 1996). Analogous to this work, the 
involvement of VOCCs in muscarinic agonist-induced vasoconstriction has been 
implicated in spontaneously beating rat hearts by using verapamil (Nuutinen et al., 1985; 
Su and Narayanan, 1993). In our study, the maximal vasoconstriction produced by 
bethanechol in non-beating rat hearts was attenuated by only 59 % even in the presence of 
a concentration o f nifedipine, which could completely block VOCCs. Nifedipine- 
resistant vasoconstriction to bethanechol was almost abolished by the putative ROCC 
blocker SK&F 96365. These observations lead us to speculate that Ca2+ entry via L-type 
VOCCs can partially account for the overall vasoconstrictor response to muscarinic 
receptor activation and additional voltage-independent Ca2+ entry mechanisms must 
contribute to this phasic contractile effect.
We also found that the bethanechol-induced tonic vasoconstriction was rapidly 
converted into a sustained vasodilation by the co-infusion of nifedipine. It is probable
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that the sustained vasodilation during L-VOCCs blockade is due to an endothelium- 
dependent mechanism since cholinergic agonists have never been reported to have a 
direct relaxant effect on vascular smooth muscle (Peach et al., 1985; Chen et al., 1988; 
Furchgott & Vanhoutte, 1989; Schini and Vanhoutte, 1992; Yang et al., 1992; 
Hammarstrom et al., 1995). Ca2+ influx through voltage-independent pathways such as 
ROCCs may be responsible for this vasodilation. The rapid onset o f inhibition probably 
results from the membrane location o f VOCCs. As in phasic vasoconstriction, the 
inhibitory effect o f nifedipine on tonic response could not be reversed.
Ca2" influx via VOCCs has been suggested to predominantly contribute to 
maintenance of muscarinic receptor-mediated vasoconstriction (Felder, 1995). However, 
results from our study demonstrate that VOCCs are heavily involved not only in 
muscarinic receptor-mediated tonic vasoconstrictor response but also phasic 
vasoconstriction. According to the different characteristics o f inhibition caused by 
nifedipine, phasic and tonic vasoconstriction to the muscarinic agonist could involve 
distinct signaling mechanisms. VOCCs appear to make a greater contribution to tonic 
than phasic responses.
As mentioned above, Ca2+ influx through VOCCs is responsible for the 
nifedipine-sensitive component o f the bethanechol-elicited vasoconstriction. Opening of 
VOCCs in smooth muscle might be due to Ca^-activated Cl' current-induced 
depolarization (Hogg et al., 1994; Wayman et al., 1997). We detected that the 
vasoconstrictor response to bethanechol was significantly decreased by A-9-C but not as 
much as by nifedipine (maximal vasoconstriction inhibition: 31 % vs 59 %). This 
observation suggests that Ca2+-dependent Cl' current-induced depolarization could
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contribute to the activation o f VOCCs in response to bethanechol in coronary resistance 
vessels. However, other mechanisms must also have a role in activating o f VOCCs.
ROCCs and SOCCs in Signaling for Muscarinic-Receptor Mediated Vasoconstriction 
To our knowledge, this is the first investigation o f the effect o f SK&F 96365 on 
muscarinic receptor-mediated vasoconstriction in coronary vessels. The typical vascular 
responses to bethanechol were completely changed by SK&F 96365. In the presence of 
SK&F 96365, bolus injection o f bethanechol evoked a phasic vasodilation rather than a 
vasoconstriction. Compared to the effect o f nifedipine, the greater efficacy o f SK&F 
96365 is probably due to the dominant role of ROCCs in the phasic response or the 
binding of SK&F 96365 to ROCCs may also regulate the activity o f VOCCs indirectly 
through PKC. The concentration o f SK&F 96365 used in the present study is relative 
selective for ROCCs without direct effect on VOCCs (Merritt et al., 1990). In addition, 
the tonic vasoconstrictor response to bethanechol was also rapidly converted into a tonic 
vasodilation by the co-infusion o f SK&F 96365. The quick onset o f action for infused 
SK&F 96365 probably reflects the interaction with ROCCs on the outer surface of the 
cell membrane. Since this transduction mechanism does not depend on the production 
and diffusion of second messengers within the cytosol, the response time is much faster 
than that for effects involving biochemical transduction (Malarkey et al., 1996). The 
ready reversibility o f the inhibitory effect o f SK&F 96365 as demonstrated by Merritt et 
al. (1990) was observed in the present study, too. Continued infusion o f  bethanechol 
after termination of the co-infusion o f SK&F 96365 produced a much larger tonic 
vasoconstriction and ended at a higher baseline perfusion pressure. This phenomenon
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could be due to an enhanced Ca2+ influx after removing the blocking effect o f SK&F 
96365 on ROCCs.
We speculate that an endothelium-dependent mechanism is responsible for the 
bethanechol-evoked vasodilation in the presence o f SK&F 96365. The SK&F 96365- 
resistant vasodilation may also be dependent upon Ca2" influx via VOCCs, since it can be 
eliminated by nifedipine. However, VOCCs in coronary vascular endothelial cells are 
reported not involved in the ACh-evoked endothelium-dependent vasodilation 
(Vanhoutte, 1992). The reason for this conflicting result concerning the role o f  VOCCs 
in endothelium-dependent vasodilation is unknown, while it is possible that coronary 
resistance vessels differ in this regard.
As reported in spontaneously beating rat hearts, EDRF release seems to be very 
important in modulation o f the overall effect o f ACh (Y ang et al., 1993). To study the 
role of EDRF in the SK&F 96365-resistant dilation to bethanechol, the effect o f  L- 
NAME on this response was evaluated. Basal coronary vascular tone was significantly 
increased by L-NAME in KCl-arrested rat hearts, which is presumably due to the 
inhibition o f basal nitric oxide release (Jino et al., 1996). That L-NAME caused a larger 
increase in baseline perfusion pressure (81 % vs 18 %) than in spontaneously beating rat 
hearts (Yang et al., 1993) indicates that high K+ may enhance the basal release o f EDRF 
under this situation. However, L-NAME did not inhibit the bethanechol-mediated 
vasorelaxation in the presence of SK&F 96365. Therefore, this response might be due to 
the release of other endothelium-derived vasorelaxant substances such as prostaglandins, 
rather than nitric oxide.
SK&F 96365 behaved very differently from nifedipine in affecting the
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bethanechol-produced coronary vasoconstriction. Although SK&F 96365 is able to block 
VOCCs in arterial smooth muscle cells at a higher concentration (Merritt et al., 1990), 
our results demonstrated the selectivity o f SK&F 96365 (10 pM) against Ca2+ entry 
through ROCCs vs VOCCs in rat coronary resistance vessels. SK&F 96365 and 
nifedipine differ in ability to inhibit phasic response to bethanechol (maximal inhibition 
100 % vs 59 %), indicating that opening of ROCCs to muscarinic receptor stimulation 
may enhance subsequent activation of VOCCs. There also exists a possible interplay 
between these two types o f Ca2+ channels in response to the muscarinic agonist.
Therefore, ROCCs may provide the predominant source o f Ca2+ for muscarinic receptor- 
evoked coronary vasoconstriction in the isolated rat heart.
Even though SK&F 96365 is very useful to probe the role of ROCCs in mediating 
functional responses, it is not as selective as desirable. 10 pM SK&F 96365 also inhibits 
SOCCs in mouse anococcygeus smooth muscle cells (Wayman et al., 1998). Muscarinic 
agonists can activate the capacitative Ca2+ entry via SOCCs in smooth muscle (Missaien 
et al., 1992; Wayman et al., 1996), which has been documented to play a significant role 
in the regulation of smooth muscle tone and provide an important entry route for Ca2+ 
along with ROCCs and VOCCs (Gibson et al., 1998). Thus, although our results provide 
evidence that ROCCs are a major Ca2+ influx mechanism for muscarinic receptor- 
mediated coronary vasoconstriction, we cannot exclude the involvement of SOCCs. 
However, the co-infusion of nifedipine entirely eliminates tonic vasoconstriction to 
bethanechol, suggesting that SOCCs are unlikely to contribute to this vasoconstrictor 
effect. On the other hand, the lack of selective inhibitor for SOCCs limits our research 
approaches to further investigate the role of capacitative Ca2+ entry in the bethanechol-
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induced vasoconstrictor responses.
PKC in Signaling for Muscarinic-Receptor Mediated Vasoconstriction
An accumulating body of evidence suggests that PKC participates in the 
contraction o f vascular smooth muscle and may be pivotal in the generation and 
maintenance o f agonist-induced vasoconstriction ( Lee and Severson, 1994; Suenaga et 
al., 1996). The essential role o f PKC in vasoconstriction is based on the following 
observations: PKC (1) can phosphorylate smooth muscle myosin and MLCK in vitro 
(Endo et al., 1982; Ikebe et al., 1985); (2) can increase the Ca2+ sensitivity o f the 
contractile apparatus (Jiang and Morgan, 1987; Itoh et al., 1988); (3) can influence the 
sustained phase of agonist-induced contraction (Rasmussen et al., 1987); (4) when 
activated by phorbol esters, can produce a slowly developing and sustained contraction in 
a number o f arteries (Andrea and Walsh, 1992).
PKC has been suggested to play a role in the G-protein-mediated sensitization of 
vascular smooth muscle contraction. A large number o f  proteins have been identified as 
potential targets for PKC-induced phosphorylation, including MLC20, MLCK, VOCCs 
and PLA2 (Andrea and Walsh, 1992). One of the major mechanisms for sensitization o f 
contractile elements is through a PKC-mediated inhibition o f MLC phosphatase (Somlyo 
and Himpens, 1989; Itoh et al., 1993) in which a small molecular weight G protein such 
as p21rho or p21ras may be involved in the sensitization process (Hirata et al., 1992; Satoh 
et al., 1993). The other is through the PKC-mediated phosphorylation calponin and 
caldesmon to generate greater force (Malarkey et al., 1996). Moreover, PKC has been 
evidenced to enhance the activity o f VOCCs in cultured vascular smooth muscle cells
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(Fish et al., 1988) and in rat aortas (Suenaga et al., 1996). As a result o f these findings, 
PKC has been implicated in agonist-evoked vasoconstriction. The involvement of PKC 
in the ACh-induced contraction has already been suggested in coronary arteries by using 
phorbol esters and measuring PKC translocation (Itoh et al., 1988; Haller et al., 1990).
Chelerythrine, a widely utilized specific inhibitor for PKC, acts through binding 
to phosphate acceptor sites and ATP sites (Herbert et al., 1990). The functional role of 
PKC in muscarinic receptor-mediated vasoconstriction in coronary vessels was first 
evaluated in our study. Chelerythrine dramatically reduced the maximal phasic 
vasoconstriction to bethanechol by as much as 79 %, indicating that PKC-dependent and 
-independent mechanisms may cooperate in muscarinic receptor-mediated 
vasoconstriction. PKC-independent component o f this vasoconstrictor effect is probably 
attributed to the direct effect o f Ca2+ on the contractile apparatus. The tonic 
vasoconstrictor response to bethanechol was also gradually diminished by chelerythrine. 
In some rat hearts, the tonic vasoconstriction was even converted into vasodilation which 
might be due to the higher basal tone (Tsao and Lefer, 1990) in these preparations. The 
inhibitory effect of chelerythrine could not be reversed in phasic and tonic responses. 
Since PKC regulates the contractile responses in the coronary arteries by phosphorylation 
o f specific contraction-relevant cellular proteins (Rembold and Murphy, 1988; Malarkey 
et al., 1990; Mino et al., 1995), the onset o f inhibition by chelerythrine on tonic 
vasoconstriction may take some time instead o f  being an instant effect. These 
observations suggest that PKC is very critical in the signaling for muscarinic receptor- 
mediated coronary vasoconstiction.
According to the two-phase model for smooth muscle contraction, PKC has major
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effect only in the tonic phase rather than the phasic phase (Rasmussen et al., 1987). In 
our study o f  rat coronary resistance vessels, PKC played an important role in phasic as 
well as tonic vasoconstriction mediated by the activation o f muscarinic receptors.
PLA-,. CQX and 5-LQX in Signaling for Muscarinic-Receptor Mediated Vasoconstriction 
In the present study, the PLA2 inhibitor p-BPB suppressed the bethanechol- 
mediated phasic vasoconstriction greater than the COX inhibitor indomethacin or the 
LOX inhibitor esculetin, while indomethacin and esculetin produced similar inhibition. 
Since both COX and LOX are downstream enzymes under PLA2, inhibition of either 
enzyme may cause accumulation of arachidonic acid and drive more arachidonic acid into 
the other competitive pathway for its utilization. Furthermore, the bethanechol-evoked 
vasoconstriction was decreased by the TxA2 antagonist SQ 29548 and the LTD4 
antagonist L 660711 to a lesser extent, indicating that the release of TxA2 and LTD4 may 
make a relatively small contribution to this contractile responses. These findings were 
compatible with other observations in rat and rabbit that TxA2 (Yang et al., 1993; Nasa et 
al., 1997) and leucotrienes (Jino et al., 1996) contribute to the ACh-induced coronary 
vasoconstriction. Nasa et al. (1997) observed the ACh-evoked vasoconstriction was 
reduced by the COX inhibitor only in the KCl-arrested rat heart but not in the 
spontaneously beating rat heart. In contrast, Yang et al. (1993) reported that both the 
COX inhibitor indomethacin and the TxA2 receptor antagonist SQ 29548 could decrease 
the vasoconstrictor response to ACh in the spontaneously beating rat heart.
It is well-known that PLA2, COX and LOX exist in both vascular endothelial and 
smooth muscle cells (Ost et al., 1998). In our isolated heart model, it is difficult to
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determine whether or not the PLA2 pathway is endothelium-dependent. Mediators TxA2 
and LTD4 could be released from the heart, too. The reason that all inhibitors in the PLA2 
pathway did not affect the bethanechol-mediated vasoconstriction in trial 1 is not clear. 
Possible explanations are that the PLA2 pathway might be activated only after the long 
period o f exposure to a high K7 buffer. The PLA2 pathway is probably not a normal 
signaling component o f the response to bethanechol. Perhaps the products in the PLA2 
pathway are somehow helping maintain the viability o f coronary vascular smooth muscle 
cells. That the concomitant infusion o f SQ 29548 and L 660711 had no effect on the 
bethanechol-induced tonic vasoconstriction could be due to the same reason.
Future Research
The present study provides important functional evidence that multiple signaling 
mechanisms participate in muscarinic receptor-mediated coronary vasoconstriction.
PKC and multiple sources of Ca2+ influx (i.e. novel ROCCs and VOCCs) seem to be the 
most important signaling components in generating coronary vasoconstrictor responses to 
bethanechol. TxA2 and LTD4 released from the PLA2 pathway may also partly account 
for the bethanechol-evoked vasoconstriction with less significance. It is also possible that 
the PLA2 pathway is not a normal signaling component for muscarinic receptor-mediated 
vasoconstriction and the mediators could be released only in response to high K+ 
perfusion to keep vascular smooth muscle cells viable.
The potential problem associated with whole organ experiments is that changes in 
vascular tone might also be due to the release o f vasoactive substances from non-smooth 
muscle cells within the organ. Therefore, it is very important to further combine isolated
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tissue work with experiments on isolated coronary vascular smooth muscle and 
endothelial cells.
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CHAPTER 5 
SUMMARY AND CONCLUSIONS
1. In KCl-arrested isolated rat hearts, bolus injection o f bethanechol produced a 
phasic vasoconstriction in a dose-dependent manner, while infusion of 
bethanechol caused a tonic vasoconstriction without tachyphylaxis. These 
observations suggest that bethanechol has a direct coronary vasoconstrictor effect.
2. The bethanechol-evoked phasic vasoconstriction in rat coronary resistance arteries 
was completely abolished by removal of extracellular Ca2+, indicating that an 
extracellular Ca2*-dependent process is essential for the muscarinic receptor- 
mediated vasoconstrictor response.
3. Nifedipine markedly inhibited the bethanechol-evoked phasic vasoconstriction, 
and the nifedipine-resistant vasoconstrictor response was almost abolished by 
SK&F 96365. The tonic vasoconstriction induced by bethanechol was rapidly 
converted into vasodilation by nifedipine. These results demonstrate that Ca2+ 
influx via VOCCs may partially account for the muscarinic receptor-mediated 
vasoconstriction and additional voltage-independent Ca2+ entry mechanisms can 
be activated for this contractile effect. VOCCs seems to make greater contribution 
to tonic than phasic vasoconstriction.
4. The vasoconstrictor response to bethanechol was completely converted into
80
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vasodilation by SK&F 96365. These data indicate that ROCCs may provide the 
predominant source of Ca2r for the muscarinic receptor-mediated coronary 
vasoconstriction.
5. There might be an interplay existing between ROCCs and VOCCs in response to 
bethanechol. Opening o f ROCCs to muscarinic receptor stimulation may 
indirectly enhance subsequent activation of VOCCs.
6. Both phasic and tonic vasoconstrictor responses to bethanechol were significantly 
reduced by chelerythrine. These observations suggest that PKC is one of the most 
important intracellular signaling components in the regulation o f the muscarinic 
receptor-mediated vasoconstriction.
7. Mediators TxA2 and LTD4 released from the PLA2 pathway might contribute to 
the muscarinic receptor-mediated coronary vasoconstriction with less 
significance. It is also possible that the products in the PLA2 pathway are not 
normal signaling components in response to bethanechol and are activated only 
after prolonged exposure to high K+.
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Reagent Formula Weight 
(g/mol)
Stock Concentration 
(mM)
Volume
(ml)
Mass
(g)
NaCl 58.44 500 1000 29.2
KC1 74.56 500 250 9.30
CaCl2-2H20 147.02 100 250 3.68
k h 2p o 4 136.09 100 250 3.40
M gS04 (anhydrous) 120 100 250 3.01
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1 L Normal Modified Krebs-Ringer Buffer
99
Reagent Volume (ml) Mass (g) Final Concentration
NaCl 254 127 (mM)
KC1 9.4 4.7 (mM)
CaCl2-2H,0 25 2.5 (mM)
k h 2p o 4 12 1.2 (mM)
M gS04 (anhydrous) 12 1.2 (mM)
Dextrose 1 0.1 % (g/ml)
Sodium pyruvate 0.22 2 (mM)
Sodium bicarbonate 2.09 25 (mM)
BSA 1 0.1 % (g/ml)
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1 L Modified Krebs-Ringer Buffer Containing 20 mM KC1
Reagent Volume (ml) Mass (g) Final Concentration
NaCl 223 112 (mM)
KC1 40 20 (mM)
CaCl2-2H20 25 2.5 (mM)
k h 2p o 4 12 1.2 (mM)
M gS04 (anhydrous) 12 1.2 (mM)
Dextrose 1 0.1%  (g/ml)
Sodium pyruvate 0.22 2 (mM)
Sodium bicarbonate 2.09 25 (mM)
BSA 1 0.1 % (g/ml)
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